

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol for a randomized controlled clinical trial with methadone treatment

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026604
Article Type:	Protocol
Date Submitted by the Author:	11-Sep-2018
Complete List of Authors:	<p>Belcher, Annabelle; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Cole, Thomas; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Greenblatt, Aaron; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Hoag, Stephen; University of Maryland School of Pharmacy, Department of Pharmaceutical Sciences            Epstein, David; National Institute on Drug Abuse Intramural Research Program            Wagner, Michael; University of Maryland Center for Substance Abuse Research            Billing, Amy; University of Maryland Center for Substance Abuse Research            Massey, Ebonie; University of Maryland Center for Substance Abuse Research            Hamilton, Kristen; University of Maryland at College Park College of Behavioral and Social Sciences, Psychology            Weintraub, Eric; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Wish, Eric; University of Maryland Center for Substance Abuse Research            Kaptchuk, Ted; Harvard Medical School, Department of Global Health &amp; Social Medicine            Colloca, Luana; University of Maryland School of Nursing</p>
Keywords:	Opioid Use Disorder, Methadone Maintenance, Placebo Effects, Opioids, Heroin Use Disorder

SCHOLARONE™  
Manuscripts

BMJ Open

Protocol Submission

OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol  
for a randomized controlled clinical trial with methadone treatment

Annabelle M. Belcher<sup>1</sup>, Thomas O. Cole<sup>1</sup>, Aaron D. Greenblatt<sup>1</sup>, Stephen W. Hoag<sup>2</sup>, David H.  
Epstein<sup>3</sup>, Michael Wagner<sup>4</sup>, Amy S. Billing<sup>4</sup>, Ebonie Massey<sup>4</sup>, Kristen R. Hamilton<sup>5</sup>, Eric  
Weintraub<sup>1</sup>, Eric D. Wish<sup>4</sup>, Ted J. Kaptchuk<sup>6</sup>, Luana Colloca<sup>7</sup>

<sup>1</sup>Division of Addiction Research and Treatment, Department of Psychiatry, School of Medicine,  
University of Maryland, Baltimore, MD, USA

<sup>2</sup>Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland,  
Baltimore, MD, USA

<sup>3</sup>National Institute on Drug Abuse Intramural Research Program, National Institutes of Health,  
Baltimore, MD, USA

<sup>4</sup>Center for Substance Abuse Research, University of Maryland, College Park, MD, 20740, USA

<sup>5</sup>Department of Psychology, University of College Park, MD, USA

<sup>6</sup>Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School,  
Boston, MA, USA

<sup>7</sup>Department of Pain and Translational Symptom Science, School of Nursing, University of  
Maryland, Baltimore, MD, USA

**Trial Sponsor and Correspondent:**

Annabelle (Mimi) M. Belcher, PhD: [abelcher@som.umaryland.edu](mailto:abelcher@som.umaryland.edu)

Division of Addiction Research and Treatment, Department of Psychiatry, University of  
Maryland School of Medicine, 110 S. Paca Street, Room 4N-101, University of Maryland,  
Baltimore, MD 21201 USA

410-328-6837 (O)

410-328-3693 (F)

**Word Count:** 4,841

**Keywords:** Opioid Use Disorder, Methadone Maintenance, Placebo Effect, Opioids, Heroin Use  
Disorder

## BMJ Open

## Protocol Submission

## WHO Trial Registration Dataset

Data category	Information
Primary registry and trial identifying number	ClinicalTrials.gov NCT02941809
Date of registration in primary registry	21 October, 2016
Source(s) of monetary or material support	Foundation for the Science of the Therapeutic Experience
Primary sponsor	Foundation for the Science of the Therapeutic Experience
Secondary sponsor(s)	University of Maryland MPowering the State Opioid Use Disorder Initiative
Contact for public queries	Annabelle M. Belcher, PhD [abelcher@som.umaryland.edu]
Contact for scientific queries	Annabelle M. Belcher, PhD University of Maryland, Baltimore
Public title	Harnessing Placebo Effects for Methadone Treatment
Scientific title	Open-labeled Dose-extending Placebos as an Adjunct to Methadone Treatment: A Pilot Study
Countries of recruitment	United States
Health condition(s) or problem(s) studied	Opioid-Related Disorders (Opioid Use Disorder)
Intervention(s)	Behavioral: Placebo Dose Extension
Key inclusion and exclusion criteria	Ages eligible for study: $\geq 18$ years Sexes eligible for study: both Accepts healthy volunteers: no
	Inclusion criteria: adult patient ( $\geq 18$ years), newly-admitted to the methadone treatment program
	Exclusion criteria: Pregnancy; Transfers (patients who have initiated methadone treatment course at another methadone treatment facility); Hospital transfers (patients who initiated methadone treatment course in a hospital setting); Criminal justice referral

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

Data category	Information
Study type	Interventional
	Allocation: Randomized
	Intervention Model: Parallel Assignment
	Masking: Double (Investigator, Outcomes Assessor)
	Primary purpose: Treatment
Date of first enrolment	June 2017
Target sample size	120
Recruitment status	Enrolling by invitation
Primary outcome(s)	Dose of methadone [Time frame: Day 84]
Key secondary outcomes	Urine Drug Testing [Time Frame: Day 1]
	Number of Days in Treatment
	Self-report of Drug Use [Time Frame: Day 84]

1 BMJ Open  
2 Protocol Submission

3 **ABSTRACT**  
4  
5

6 **Introduction.** More than 2 million individuals in the United States have an Opioid Use Disorder  
7 (OUD). Methadone maintenance treatment is the gold standard of medication-assisted treatment  
8 for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory  
9 complications, among other side effects. These adverse effects make enhancing the effectiveness  
10 of lower doses of methadone an attractive therapeutic goal. Long recognized for its capacity to  
11 enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the  
12 placebo effect offers an as-yet untested avenue to such an enhancement. This approach is  
13 particularly compelling given that individuals with substance use disorder tend to have higher  
14 salience attribution, and may thereby be more sensitive to placebo effects. Our study combines  
15 two promising clinical methodologies—conditioning/dose-extension and open-label placebo—to  
16 investigate whether placebo effects can increase the effective potency of methadone in treatment-  
17 seeking OUD patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 **Methods and Analysis.** A total of 120 newly-enrolled treatment-seeking OUD patients will be  
29 randomly assigned to one of two different groups: either methadone plus daily placebo dose  
30 extension (PDE; treatment group), or methadone/Treatment as Usual (TAU; control).  
31 Participants will meet with study team members five times over the course of three months of  
32 treatment with methadone (baseline, 2 weeks, and 1, 2 and 3 months post-baseline). Throughout  
33 this study time period, methadone dosages will be adjusted by an addiction clinician blind to  
34 patient assignment, per standard clinical methods. The primary outcome is methadone dose at  
35 three months. Secondary outcomes include self-report of drug use; 3-month urine toxicology  
36 screen results; and treatment retention. Exploratory outcomes include several environmental as  
37 well as personality factors associated with OUD and with propensity to demonstrate a placebo  
38 effect.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 **Ethics and Dissemination.** Human subjects oversight for this study is provided by the  
49 University of Maryland, Baltimore and University of Maryland, College Park Institutional  
50 Review Boards. Additionally, the study protocol is reviewed annually by an independent Data  
51 and Safety Monitoring Board. Study results will be disseminated via research conference  
52 presentations and peer-reviewed publications.  
53  
54  
55  
56  
57

1 BMJ Open  
2 Protocol Submission

3 **Trial Registration Number.** ClinicalTrials.gov Identifier NCT02941809  
4  
5

6 **Strengths and limitations of this study**  
7

- 8
- 9 • This is the first randomized controlled trial designed to assess whether a combined  
10 conditioning paradigm and open-label placebo can be harnessed to enhance treatment  
11 outcomes in OUD.  
12
  - 13 • By employing an open-label transparent design, this study avoids the problematic ethical  
14 issues that would arise surrounding concealed or deceptive placebo administration, thus  
15 preserving patient autonomy and patient-clinician communication.  
16
  - 17 • Urine specimens will be tested for 240 substances, thus yielding a comprehensive picture  
18 of the opioids, new psychoactive drugs and pharmaceutical drugs recently used by  
19 patients.  
20
  - 21 • Additionally, a comprehensive patient self-report drug use instrument affords the unique  
22 opportunity to assess lifetime and current patterns of licit and illicit substance use  
23 (including prescription opioids), which can be used both to determine premorbid drug use  
24 patterns, as well as to assess the accuracy of patient self-reports of recent drug use.  
25
  - 26 • As a pilot proof-of-concept study designed to test open-label placebo conditioning on  
27 OUD treatment outcomes, this study does not incorporate closed-label (blind) treatment  
28 arms; we plan to address this limitation in future follow-up studies.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1 BMJ Open  
2 Protocol Submission

### 3 INTRODUCTION 4 5

6 Between 2001 and 2016, the number of opioid-related deaths in the United States  
7 increased by 345%, from 9,489 to 42,245<sup>1</sup>. The incredible surges in overdose deaths and in the  
8 prevalence of Opioid Use Disorder (OUD) have caused many federal and state agencies to  
9 identify this epidemic as one of the largest looming threats to public health today<sup>2</sup>.  
10  
11  
12

13  
14 Methadone maintenance treatment (MMT) is the most highly researched and evidence-  
15 based treatment for OUD, and has become a mainstay in treatment<sup>3</sup>. At appropriate doses, MMT  
16 is associated with significant improvements in a number of outcomes, including decreased drug  
17 use and crime, and increased positive health outcomes<sup>3-5</sup>. Perplexingly, there is great individual  
18 variability in MMT response. While some patients can fare well for years on end with low to  
19 moderate doses in the range of 30-60 mg/day<sup>6,7</sup>, many patients need much higher doses of  
20 methadone to control craving and drug-seeking behavior<sup>8,9</sup>. Unresolved medical debates on  
21 whether “more is better” provide no clarity on this issue, and with no generally accepted optimal  
22 dose prescription, clinicians titrate MMT dose to a subjective patient behavioral effect—a  
23 practice that sometimes translates to the prescription of very high doses of methadone<sup>7</sup>.  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 There are several reasons to give serious consideration to adjunctive treatments aimed at  
34 prevention of methadone dose escalation. For many patients, the high doses of methadone that  
35 seem to be needed for full therapeutic effect come at an unfortunate cost: side effects such as  
36 constipation, sedation, nausea, and sweating may be so great as to be a major determinant in  
37 treatment failures<sup>10</sup>. More alarmingly, higher methadone doses have been associated with risk  
38 factors for arrhythmias, such as QT interval prolongation and *Torsade de pointes*<sup>11</sup>, and reports  
39 of increasing methadone-related deaths have led to greater scrutiny of methadone dosing  
40 practices<sup>12,13</sup>. And from a patient perspective, an estimated 30% of MMT patients have severe  
41 anxiety related to MMT detoxification due to fear of withdrawal and relapse<sup>14,15</sup>: concerns that  
42 theoretically could be eased if those patients could be effectively treated at lower MMT doses.  
43 Collectively, these various issues and considerations provide ample rationale to explore options  
44 to increase the effectiveness of lower doses of methadone.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



BMJ Open  
Protocol Submission

One plausible adjunctive behavioral treatment involves placebo effects. Recent investigations have yielded greater appreciation of the therapeutic potential of harnessing placebo responses that otherwise occur naturally within the frame of medical treatment. Defined as the positive health outcomes derived from an inert substance or device used in the context of medical treatment<sup>16,17</sup>, placebo effects are guided by an individual's conscious or unconscious expectation of salubrious effects, and can yield very powerful determinations of health outcomes across many different diseases and encounters<sup>16-19</sup>. Studies spanning two decades have shown that it is possible to condition the opioidergic system, the main neurotransmitter receptor system involved in addiction to drugs like heroin and prescription opioids. For example, placebo responses can be elicited by pairing morphine with placebo—an effect that is dependent on the strength of the association paradigm used to create the conditioned response<sup>20-23</sup>. Although groundbreaking, clinical practice translation of these studies is limited by methodology incorporating deception: researchers told participants that they would receive drug when in fact they were to receive placebo, and vice-versa.

We know of two promising strategies for ethically harnessing placebo effects. The first employs principles of Pavlovian conditioning<sup>24</sup>. By pairing placebo pills and clinical contextual cues (conditioned stimuli) with a physiologically active treatment (unconditioned stimuli), researchers have shown that medication dosages can be lowered without decreasing treatment efficacy<sup>25-29</sup>. This strategy is often referred to as placebo “dose-extension,” due to the fact that the placebo pill can be used to “extend” the efficacy of the medication with which it was paired, and subsequent placebo administration can produce therapeutic effects.

A second strategy is known as open-label placebo administration, in which the placebo is identified as such. Patients are usually told that “we know that placebos have powerful effects in double-blind trials and we want to test whether placebos work even when patients know that they are taking placebos”<sup>30,31</sup>. This approach has yielded positive results in a variety of somatic and pain-related conditions<sup>32-36</sup>. Researchers are proposing that open-label-induced placebo effects may involve aspects of Bayesian brain function and processing of error prediction<sup>30,37</sup>. But irrespective of mechanism, the available data suggest that open-label methods work, and that they provide a solution to the ethical dilemma of patient-blinded placebo delivery.

BMJ Open  
Protocol Submission

In the context of substance use disorders, the placebo effect is interesting due to *prima facie* overlap in the genes and brain substrates implicated<sup>38</sup>. On a practical level, the case for harnessing placebo effects in addiction treatment is supported by a long line of research demonstrating that such effects are strong in drug-dependent individuals. For example, individuals dependent on nicotine<sup>39,40</sup>, alcohol<sup>41,42</sup> and marijuana<sup>43</sup> show differential drug consumption and/or subjective drug effects based on experimentally-manipulated expectations. In one of the earliest studies demonstrating this phenomenon, Marlatt showed that drinking behavior in alcohol-dependent subjects could be manipulated by beliefs concerning the alcohol content of the beverage: when expecting to sample a drink containing alcohol, subjects drank almost twice as much as those expecting to receive only non-alcoholic beverages<sup>44</sup>.

In a pivotal study, using a “balanced placebo” design, Volkow and colleagues<sup>45</sup> administered placebos to both cocaine abusers and non-drug abusing subjects and found a significant effect of modulating expectations; brain metabolic changes were about 50% greater when the subjects were informed about receiving drug, in comparison with the group of subjects who were informed about receiving placebo<sup>38,45</sup>. Intriguingly, methadone-treated OUD patients might be particularly sensitive to placebo effects relevant to their treatment<sup>46</sup>. To date, however, no group has explicitly tested whether these placebo effects could be used to improve medicalized addiction treatment outcomes. Further, no study has investigated the efficacy of either conditioning or open-label placebo strategies in a methadone maintenance context. This study uniquely combines two validated approaches to harnessing placebo effects in what we call an “open-label conditioning dose extension with placebo” paradigm, or, more succinctly, an “open-label placebo dose-extension (PDE)” paradigm.

**Objectives.** The broad goal of this study is to improve treatment outcomes for OUD patients who are newly enrolled in a daily outpatient MMT program. Specifically, we hypothesize that an open-label placebo dose-extension paradigm (PDE) will obviate higher-dose methadone treatment for a significant portion of new initiates and will thereby reduce methadone-associated side effects, with no concomitant diminution in outcomes such as self-reports and clinical observations of withdrawal, craving, and quality of life. We also hypothesize that the placebo intervention will enhance MMT outcomes (decreased positive urine screens and increased treatment retention) with equivalent outcomes at different mean doses of methadone.

## BMJ Open Protocol Submission

We plan to recruit 120 participants and randomly assign them to one of two conditions: open-label placebo dose-extension (group PDE) plus methadone or methadone/Treatment as Usual (TAU). We will follow them for three months for a total of five in-person meetings (baseline, and two weeks, 1, 2 and 3 months post-baseline). For the first two weeks, we will implement principles of pharmacological conditioning<sup>24,47</sup> whereby placebo pills are temporally paired with the oral methadone hydrochloride solution that is provided to patients at the clinic (conditioning phase). Having established an association and contextualized the placebo as part of the therapeutic experience, placebos are then used as a dose extension (PDE) pill (dose extension phase, week 3 up to three months). Additionally, we are applying an open-label paradigm, giving participants information concerning the placebo pill in an honest and transparent manner. Our primary outcome is methadone dose three months after (baseline) entry into treatment; secondary outcomes include several measures of treatment success including comprehensive urine toxicology screens, self-reported drug use, and treatment retention. We are also capitalizing on this unique patient access opportunity to measure several personality and environmental factors associated with OUD, as well as factors associated with placebo response.

## METHODS AND DATA ANALYSIS

**Study Setting.** Our ongoing study takes place at the University of Maryland Drug Treatment Center, an urban clinic located in West Baltimore, Maryland. The clinic is open 6 days a week (excluding holidays), and in addition to medication-assisted treatment, the clinic provides counseling and psychiatric services. The majority of our patients reside within one of five zip codes that immediately surround the clinic address, and present to the clinic either by referral or self-admission. Approximately 5 new patients are enrolled into MMT per week.

**Patient recruitment.** Study participants will be 120 men and women OUD adults newly admitted to the UM Methadone Treatment Program (MTP). New patients are recruited on the first day of treatment in the clinic (Day 0). At the end of initial intake procedures of the first day, the Program Intake Coordinator asks new patients if they are interested in hearing information about a study that is testing a novel approach to enhancing methadone treatment, for which they would receive compensation. A member of the study team (either the P.I. [AMB] or the primary

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

BMJ Open  
Protocol Submission

Research Coordinator [TOC]) makes contact with the intake coordinator to receive names of patients who are newly enrolled for MMT treatment and are willing to hear about the study.

Patients who indicate their interest are brought to a private interview room located near the methadone dosing area, where they are screened for eligibility, informed about the study and conceptual basis of the placebo effect, and consented for participation. The study has been approved by the University of Maryland Institutional Review Board and all procedures are performed in accordance with the relevant international and local guidelines and regulations for human research (UMB IRB Protocol # HP-00070829). A written informed consent is obtained from each study participant.

***Eligibility Criteria.*** Participants are included in the study if they are newly enrolled (admission within the same day) in the MTP, have not had very recent experience with MMT in a clinic setting (within the past three weeks), and do not have any extenuating factors that would have a strong influence on clinical methadone dose determination. Inclusion criteria include: (i) adult (age 18 or over) and (ii) newly-admitted to the methadone treatment program. Exclusion factors include (i) pregnancy, (ii) treatment transfer (patients who have initiated methadone treatment course at another methadone treatment facility), (iii) hospital transfers (patients who initiated methadone treatment course in a hospital setting), or (iv) criminal justice system referrals.

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

**Study Design and Procedures**

***Randomization and Treatment Allocation.*** Prior to study inception, random treatment allocation was generated by an independent investigator, and consists of sequentially numbered opaque envelopes containing treatment assignments drawn from a computer-generated random number sequence. These numbers are used to assign participants to either the open-label placebo dose-extension arm (PDE group) or a Treatment as Usual (TAU) arm, and two stacks of envelopes were created to ensure an even distribution of men and women (N=30/group/sex for a total of 120 random treatment allocations).

Treatment allocation occurs after completion of the assessments. The investigator performs allocation by pulling an envelope from the top of the sex-specific stack. Following Day 0 study procedures, and just prior to the first dose of methadone at the treatment window, the

BMJ Open  
Protocol Submission

investigator conducts a treatment assignment “reveal,” opening the envelope and letting the patient know the group to which s/he has been assigned.

At all stages of the study, methadone dose adjustments are conducted by an independent clinician blind to treatment allocation (and in fact, blind to when participant is enrolled in the study entirely). Additionally, because treatment allocation occurs only after Day 0 (baseline) assessments are complete, study team members are blind to treatment assignment for all of Day 0 procedures. Finally, data analysts are blind to treatment allocation.

***Script and Study Information Provided.*** Patients are fully debriefed of all study procedures during an informed consent process. Participants are informed that their participation in the trial will have no effect on ongoing treatment afforded by the clinic, and further, that they have the right to withdraw from the study at any time with no impact on their clinical treatment. During and following consent, the notion is reinforced to the patients that the research study is “designed to investigate the efficacy of methadone treatment that is enhanced via inner healing processes using placebo effects.” An IRB-approved script is used as a conversational guide to inform patients of the study rationale and procedures. This script has a positive framing, and describes in lay terms the science that underlies placebo effects and pharmacological conditioning, with an aim to facilitate the placebo response in a non-deceitful manner. Following the conversational reading of the script, the investigator asks the participant to view a video of a CBS New York News piece<sup>48</sup> that describes scientific studies of the successful use of the placebo phenomenon as a therapeutic intervention for Irritable Bowel Syndrome. The participant then completes the Day 0 (baseline) assessments (described below).

***Placebo pills.*** The placebo dose-extension (PDE) pill is produced by the University of Maryland School of Pharmacy Good Manufacturing Practice facility. The pills are composed of microcrystalline cellulose PH-102, magnesium stearate, and D&C Red 7 Ca Lake (inert chemicals and a food colorant, ingredients commonly contained in placebo pills manufactured by the pharmaceutical industry). PDE pills are stored in a locked medications cabinet maintained within the nurses’ station.

1 BMJ Open  
2 Protocol Submission

3 ***Intervention: Daily PDE Pill Dispensing.*** Following treatment assignment on Day 0, the  
4 investigator fills a placebo pill dispensing form indicating treatment assignment, and the patient  
5 is walked to the methadone dosing station. Placebo pills are stored and dispensed by the nursing  
6 staff of the MTP. If the patient is in group PDE, the investigator observes the participant taking  
7 the PDE pill. In Phase 1 of the study (first two weeks), participants assigned to group PDE are  
8 given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3  
9 months), PDE participants continue to take the single (morning, or AM) pill, and are given a  
10 second pill in a bottle as a take-home. They are instructed to take this second pill twelve hours  
11 following the first pill, “at home, or wherever they may be.” Participants are asked to return the  
12 take-home pill bottle every day for refill. Circumstances may occur under which a participant  
13 may need to be withdrawn from the protocol, and include: not following instructions given by  
14 team members, or repeatedly missing appointments without contacting study staff. Adherence to  
15 the instructions to take the AM pill will be monitored by study team nursing staff.

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 ***Urine Toxicology Screens.*** Urine drug screening occurs via two methods: (1) a point-of-care  
28 Quik-tox screen (11 panel; LabCorp) conducted by clinic staff, results of which are reported  
29 immediately, conducted at baseline and then at monthly (random) intervals post-baseline; (2) and  
30 liquid chromatography–tandem mass spectrometry (LC-MS/MS) testing for a panel of more than  
31 240 drugs, including new psychoactive substances, as well as other illicit and prescription drugs.  
32 All testing is conducted by the Division of Forensic Toxicology, Armed Forces Medical  
33 Examiner System and coordinated by the University of Maryland, College Park Center for  
34 Substance Abuse Research (CESAR) staff. Urine is collected from participants during each of  
35 the five meeting times, and the Quik-tox screen is conducted only on samples from meeting one  
36 (baseline); the LC/MS/MS testing is conducted on all samples (baseline and 2 weeks, 1, 2 and 3  
37 months post-baseline screening).

38  
39  
40  
41  
42  
43  
44  
45  
46  
47 ***Primary Outcomes.*** The primary outcome is final methadone dose at the three-month time point.  
48 MTP clinicians adhere strictly to the Substance Abuse and Mental Health Services  
49 Administration’s (SAMHSA) standards for medication-assisted treatment of OUD. Patients  
50 entering into treatment are given an initial evaluation that results in the prescription of an  
51 induction (initial dose  $\leq 30$  mg/d, followed by a gradual dose up-titration) and initial stabilization  
52 dose (typically 50-70 mg), which is usually reached by the third week of treatment. At two to  
53  
54  
55  
56  
57

BMJ Open  
Protocol Submission

three weeks, a nurse practitioner or physician evaluates treatment progress and writes an order either to continue or to increase the initial maintenance dose. As noted above, this clinician evaluator is blinded to the patient's experimental-group assignment. In the MTP, approximately 75% of new patients who enter for methadone treatment are given a recommendation to titrate up to a higher dose (personal communications with staff). We will be documenting the induction (starting), maintenance, as well as the ultimate holding dose that follows the dose evaluation. These data are obtained from patient charts documenting daily records of methadone dose dispensed.

**Secondary Outcomes.** Secondary outcomes include self-report of drug use, baseline, and 3-month urine screen results, and treatment retention. Self-report of drug use is assessed with an instrument developed by CESAR that asks lifetime and recent (past 24-48 hour) use of over 50 different licit and illicit drugs. Drug toxicology results of the urinalyses conducted by the Methadone Clinic (monthly random drug testing) and the independent research laboratory, as well as treatment retention (treatment days missed and take-home MMT) will be measured as secondary outcomes at baseline and at the 3-month time point.

**Exploratory Outcomes.** The unique longitudinal nature of this study allows us to assess several factors of interest, including personality factors associated with SUD and those associated with propensity to demonstrate a placebo effect. These self-report outcomes include scores on withdrawal and craving scales, quality of life, sleep patterns, placebo intervention expectation and compliance, as well as measures of impulsivity and catastrophizing. All assessments are administered by a member of our study team.

**Clinical Assessments** (see Table 1):

- *Baseline and Post-Baseline Drug Use History and Assessment (CESAR):* a comprehensive assessment of substance use history and treatment, environmental and psychosocial risk factors, and recent use of more than 30 commonly used licit and illicit drugs;
- *Adapted Credibility/Expectancy Questionnaires*<sup>49</sup>: a three-item assessment of participant beliefs that the PDE would improve their symptoms (Day 0), and a 3-4-item group-

## BMJ Open

## Protocol Submission

dependent assessment of participant beliefs that the PDE is helping or would help improve their symptoms (Days 14, 28, 56 and 84);

- *Subjective Opioid Withdrawal Scale (SOWS)*<sup>50</sup>: a 16-item patient self-report instrument to assess common subjective symptoms of craving and withdrawal;
- *Objective Opioid Withdrawal Scale (OOWS)*<sup>50</sup>: a 13-item clinical assessment of physiological signs of withdrawal;
- *Craving Assessment*<sup>51,52</sup>: an adapted one-item visual-analog scale;
- *World Health Organization Quality of Life Scale – Brief (WHOQOL-BREF)*: a 26-item assessment of life satisfaction;
- *Compliance*: a visual-analog scale assessing compliance with instructions to take the PDE pill;
- *Past 2-Week Substance Use*: self-reported frequency of use of four broad classes of drugs;
- *Methadone Symptom Severity Checklist*<sup>53</sup>: symptom severity of 38 commonly-reported methadone treatment-associated side effects;
- *Cleveland Clinic Constipation Scoring System*<sup>54</sup>: an 8-item scale of constipation severity

**Psychological Measurements**

- *Monetary Choice Questionnaire (MCQ)*<sup>55</sup>: a 27-item assessment of delay discounting that asks participants to make hypothetical choices between a smaller-sooner amount of money available today or a larger-later amount of money available after a delay;
- *Barratt Impulsivity Scale, version 11 (BIS-11)*<sup>56</sup>: a 30-item assessment that yields information regarding several three facets of trait impulsivity (i.e., attentional impulsivity, motor impulsivity, and non-planning impulsivity), wherein participants indicate on a four point Likert-like scale the extent to which each of 30 items describes their overall behavior;
- *Behavioral Inhibition/Activation System Scales (BIS/BAS)*<sup>57</sup>: a 24-item assessment of behavioral inhibition (BIS) and approach (BAS), wherein participants indicate on a four point Likert-like scale the extent to which each of 24 items describes their behavioral style;



## BMJ Open

## Protocol Submission

- *Pain Catastrophizing Scale (PCS)*<sup>58</sup>: a 13-item assessment of how pain is subjectively experienced, wherein participants indicate on a four point Likert-like scale the extent to which each of the 13 items describe the thoughts and feelings they have when they are experiencing pain;
- *Pittsburgh Sleep Quality Index (PSQI)*<sup>59</sup>: a 9-item assessment of sleep satisfaction;
- *PEG Pain Screening Tool*<sup>60</sup>: a 3-item assessment of pain intensity and interference;
- *Exit Survey*: a 7-item quantitative and qualitative assessment of how the PDE pill was experienced by participants and their thoughts about their experience participating in the study.

A detailed time line of all outcome assessments is provided in Table 1.

**Sample Size Calculation.** We anticipate that dose escalations will be recommended at dose evaluation (approximately three weeks following entry into treatment) for approximately 70% of participants in the TAU control group. With 60 participants per group, we will have power of .80 to detect a difference between groups if the corresponding rate in the intervention group is 44% or lower (i.e., a maximum of 26/60 participants), using a Fisher exact test with a two-tailed alpha of .05. This is a medium-to-large effect, equivalent to an odds ratio of 3.03 or a Cohen's *d* of .61.

For our non-inferiority tests on outcome indicators, power depends on the rate of occurrence (for dichotomous outcomes) and on the sample standard deviation (for continuous outcomes). Thus, if a dichotomous outcome (such as reports of withdrawal) occurs in 15% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 19%, using a one-sided 95% confidence interval, as is appropriate for a non-inferiority test. If reports of withdrawal occur in 5% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 12%, using a one-sided 95% confidence interval. Similarly, if scores on a measure of withdrawal severity have a standard deviation of 0.5 with no observed difference in means between groups, we will have power of .90 to conclude that the real difference in means is no greater than .27 standard deviations, using a one-sided 95% confidence interval. If the scores have a standard deviation of 0.8 with no observed difference in means between groups, we will have power of .90 to conclude that the real difference in means is no greater than .43 standard deviations, using a one-sided 95% confidence interval. To help

BMJ Open  
Protocol Submission

ensure that we obtain usable data from 120 completed participants (60 per group), we plan to screen and enroll 240 participants. Attrition within the first three months of treatment at the MTP is not heavy, but we want to take a conservative approach to the possibility of noncompliance with study measures and procedures.

**Data Analysis.** We will use a between-group (PDE vs. TAU) comparison of the proportion of patients who move up to a higher methadone dose, and a comparison of scores or counts on all other measures. We will make these comparisons with an exact test unless demographic comparisons of the two groups suggest that we need to control for potential confounding co-variables such as sex, race, age, or baseline indicators of addiction severity, in which case we will use multiple logistic regression. We will also test for non-inferiority on the following outcome measures: (1) frequency of positive drug testing (urine and self-report); (2) SOWS score; (3) OOWS score; (4) Craving score; (5) WHOQOL-BREF; (6) days in treatment; (7) methadone side effects checklist; (8) Constipation Severity Score. The analytic method will be determined by the distribution of the data on the outcome measure (e.g., generalized linear mixed models for frequency of positive urine drug tests, and general linear mixed models for questionnaire scores), but the hypothesis of non-inferiority will always be tested by comparison of one-sided 95% confidence intervals for the parameter estimates.

**Anticipated Outcomes.** We anticipate that a substantial proportion of patients in the PDE group will not need to be escalated to the higher doses of methadone (see Figure 1). We also expect that patients in this group will have clinical improvements at least as good as those in the control group, in terms of decreased craving, withdrawal, drug use and urine-positive drug tests, increased scores on a quality of life assessment, and treatment retention at the three-month (84-day) time point—with fewer side effects from methadone. Finally, we anticipate that primary and secondary outcomes will scale with both expectancy and compliance.

**Data Collection: Retention, Quality Management and Storage.** Participants are given an appointment card that serves as a reminder of the next date that they are to meet with study staff. Additionally, a member of the study team calls participants one day prior to the designated meeting day to remind them of their appointment. Data are collected in an in-person meeting on paper for each instrument. Following the meeting, data are recorded electronically in an *ad hoc*

BMJ Open  
Protocol Submission

project created in RedCAP<sup>61</sup>, a secure data collection and management application hosted at the University of Maryland, Baltimore. Once recorded, data are verified by a secondary independent observer and subsequently locked to prevent changes from being made. Missing data due to missed meetings are coded as incomplete. The resulting database is imported into SPSS and logical consistency checks are conducted and addressed, and missing values designated. Data collected on paper are de-identified with a Study ID number, and stored in a locked cabinet in an off-site location. And electronic identifying information will be password-protected on an encrypted, HIPAA-compliant drive, and all study authors will have access to verified, cleaned and de-identified data sets.

**Data Monitoring.** The study is reviewed annually by an independent Data Safety and Monitoring Board. Progress reports include reporting of adverse events, updates on enrollment, raw data reporting, and any outcomes and preliminary analyses.

**Unanticipated/Adverse/Reportable New Information Event Reporting.** Although the likelihood of an adverse event is exceedingly unlikely, participants in the PDE group will receive a pill instruction handout (attached under "relevant materials" above). This handout will contain explicit information on who to contact in case of an adverse event situation. The Methadone Clinic is staffed daily by a work force of doctors, nurses and clinical counselors who are specifically trained to work with this population of individuals suffering from substance use disorder. In the unlikely event that a participant shows signs of crisis (e.g. heightened anxiety) due to discomfort with any aspect of the assessments, a counselor or doctor on the floor will be engaged to intervene promptly.

**Ethics and dissemination:** All activities associated with this protocol are conducted in full compliance with current University of Maryland, Baltimore and University of Maryland, College Park Human Research Protection Programs and Institutional Review Board policies and procedures while maintaining compliance with federal regulations. This protocol is approved and is active with IRBs of both universities. Written informed consent is obtained from every participant. Important protocol modifications will be communicated to relevant members of the research team *via* Collaborative Institutional Comprehensive Evaluation of Research Online (CICERO), the University of Maryland School of Medicine's Research Evaluation Portal. Any

1 BMJ Open  
2 Protocol Submission

3 results from this trial (publications, conference presentations) will be published in peer-reviewed  
4 journals and conference proceedings.  
5  
6

## 7 **DISCUSSION**

10 To our knowledge, this is the first randomized, controlled clinical trial that implements  
11 methods of inducing ethically-appropriate placebo responses in an addiction treatment context.  
12 The findings obtained will provide crucial pilot data concerning the effectiveness of placebo  
13 interventions implemented in the context of OUD treatment. Additionally, understanding the  
14 capacity for pharmacological conditioning to impact outcomes in this patient population could  
15 have very significant clinical and translational implications, and could provide strong  
16 justification for its use in the clinic as a method of increasing the ratio of benefits to side effects  
17 in MMT.  
18  
19  
20  
21  
22  
23

24 In addition to exploring the therapeutic potential of a harnessed placebo response,  
25 through comprehensive urine screen analysis, this ongoing clinical trial will yield important  
26 information regarding the precise types of drugs that are being consumed in a West Baltimore  
27 neighborhood, currently “Ground Zero” in the nation’s current opioid epidemic<sup>62</sup>. In a time of  
28 rapid changes in the synthetic drugs available on the street, patients often report having no  
29 awareness of the substances they have ingested (personal communications, AMB, EW, ADG,  
30 2018). Our comprehensive urinalysis will help inform current trends in use, and help realize the  
31 scope of compounds contained in street drugs. Additionally, patient self-report of lifetime history  
32 of drug use will afford a unique opportunity to understand drug use patterns (particularly,  
33 prescription opioid use) that may have predated use of other opioids such as heroin.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 This clinical trial study is designed to explore whether open-label placebo can be  
45 integrated into treatment with salubrious effects. Because the goal is to move the needle very  
46 quickly to enhance medicalized addiction treatment, we wanted to take the simplest approach to  
47 obtaining an answer on whether placebo pills might be a useful tool in this arsenal. As such, we  
48 chose to restrict ourselves to a two-arm design (PDE vs. TAU). A limitation of this approach,  
49 however, is that we will not be able to produce data on how patients would respond to placebo  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 BMJ Open  
2 Protocol Submission

3 pills delivered blindly: in other words, traditional placebo effects invoked using non-transparent  
4 methods. We plan to address this gap in future follow-up studies.  
5  
6  
7

8 As numbers of new individuals afflicted with OUD continue to rise, the NIH has called  
9 on the scientific community to deliver effective and sustainable solutions to stave this formidable  
10 public health challenge<sup>63</sup>. Medication-Assisted Treatment is the only treatment strategy with a  
11 scientific basis, and the treatment of choice for OUD, endorsed fully by the medical community.  
12 Harnessing a potentially effective placebo response to enhance methadone treatment of OUD is  
13 responsive to this NIH call, with the additional boon of very low financial burden and risk to  
14 patients. If our RCT outcome is successful, it would represent an important first step towards a  
15 safe, inexpensive and quick-to-launch adjunct to methadone that could feasibly change front-line  
16 addiction medicine treatment of OUD.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 BMJ Open  
2 Protocol Submission

3 **REFERENCES**

4  
5  
6 1 Gomes T, Tadrous M, Mamdani MM, et al. The Burden of Opioid-Related Mortality in the  
7 United States. *JAMA Network Open* 2018;1(2):e180217.

8  
9 doi:10.1001/jamanetworkopen.2018.0217

10  
11  
12 2 U.S. Department of Health and Human Services (HHS). Office of the Surgeon General, Facing  
13 Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health.

14  
15 Washington, DC: *HHS* 2016.

16  
17  
18 3 Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies—tackling the opioid-  
19 overdose epidemic. *N Engl J Med* 2014;370:2063–66.

20  
21  
22 4 Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid  
23 replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009;3:CD002209.

24  
25  
26 5 Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and  
27 future directions. *Harv Rev Psychiatry* 2015;23(2):63-75.

28  
29  
30 6 Maremmani I, Pacini M, Lubrano S, et al. When “enough” is still not “enough”: Effectiveness  
31 of high-dose methadone in the treatment of heroin addiction. *Heroin Add & Rel Clin Probl*  
32 2003;5:17–32

33  
34  
35 7 Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual  
36 opioid-dependent patients. *PLoS Med* 2006;3(3):e80.

37  
38  
39 8 Strain EC, Stitzer ML, Liebson IA, et al. Methadone dose and treatment outcome. *Drug and*  
40 *Alcohol Dependence* 1993;33:105-17.

41  
42  
43 9 Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of  
44 higher-dose methadone. *J Psychoactive Drugs* 1999;31(2):95-102.

## BMJ Open

## Protocol Submission

10 Adams RG, Capel WC, Bloom WA, et al. Heroin addicts on methadone replacement: a study of dropouts. *Int J Addict* 1971;6(2):269-77.

11 Martin JA, Campbell A, Killip T, et al. QT Interval Screening in Methadone Maintenance Treatment: Report of a SAMHSA Expert Panel. *J Addict Dis* 2011;30(4):283-306.

12 Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain* 2014;15(4):321-37.

13 Weimer MB, Chou R. Research gaps on methadone harms and comparative harms: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. *J Pain* 2014;15(4):366-76.

14 Milby JB, Gurwitch RH, Wiebe DJ, et al. Prevalence and diagnostic reliability of methadone maintenance detoxification fear. *Am J Psychiatry* 1986;143(6):739-43.

15 Eklund C, Hiltunen AJ, Melin L, et al. Abstinence fear in methadone maintenance withdrawal: a possible obstacle for getting off methadone. *Subst Use Misuse* 1997;32(6):779-92.

16 Colloca, L. (in press) The Placebo Effect in Pain Therapies. *Annu Rev Pharmacol Toxicol* 2019;59:X-X.

17 Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. *N Engl J Med* 2015;373(1):8-9.

18 Colloca L, Flaten MA, Meissner K. (Eds.). *Placebo and pain: from bench to bedside*. Academic Press 2013.

19 Colloca L, Klinger R, Flor H, et al. Placebo analgesia: psychological and neurobiological mechanisms. *Pain* 2013;154(4):511-4.

## BMJ Open

## Protocol Submission

20 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. *J*

*Neurosci* 1999;19(1):484-94.

21 Benedetti F, Pollo A, Lopiano L, et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. *J Neurosci* 2003;23(10):4315-23.

22 Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. *Neuroscience* 2007;147(2):260-71.

23 Benedetti F. Placebo and Endogenous mechanisms of analgesia. *Handb Exp Pharmacol* 2007;177:393-413.

24 Colloca L, Enck P, DeGrazia D. Relieving pain using dose-extending placebos: a scoping review. *Pain* 2016;157(8):1590-98.

25 Ader R, Mercurio MG, Walton J, et al. Conditioned pharmacotherapeutic effects: a preliminary study. *Psychosom Med* 2010;72(2):192-97.

26 Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. *Child Care Health Dev* 2008;34(1):104-10.

27 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? *J Dev Behav Pediatr* 2010;31(5):369-75.

28 Perlis M, Grandner M, Zee J, et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. *Sleep Med* 2015;16(9):1160-68.

29 Kirchhof J, Petrakova L, Brinkhoff A, et al. Learned immunosuppressive placebo responses in renal transplant patients. *Proc Natl Acad Sci U S A* 2018;115(16):4223-27.



## BMJ Open

## Protocol Submission

30 Kaptchuk TJ. Open-label placebo: Reflections on a research agenda. *Perspect Biol Med* 2018; in press.

31 Kaptchuk TJ, Miller FG. Open-label placebo: Can honestly prescribed placebos evoke meaningful therapeutic benefits? *BMJ* 2018; in press.

32 Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. *PLoS One* 2010;5(12):e15591.

33 Carvalho C, Caetano JM, Cunha L, et al. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. *Pain* 2016;157(12):2766-2772.

34 Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. *Sci Transl Med* 2014;6(218):218ra5.

35 Schaefer M, Harke R, Denke C. Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial. *Psychother Psychosom* 2016;85(6):373-374.

36 Hoenemeyer TW, Kaptchuk TJ, Mehta TS, et al. Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial. *Sci Rep* 2018;8(1):2784.

37 Ongaro G, Kaptchuk TJ. Symptom perception, placebo effects and the Bayesian brain. *Pain* 2018 (in press).

38 Belcher AM, Ferré S, Martinez PE, et al. Role of placebo effects in pain and neuropsychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2018;87(Pt B):298-306.

39 Juliano LM, Brandon TH. Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor. *J Abnorm Psychol* 2002;111(1):88-97.

40 Kelemen WL, Kaighobadi F. Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design. *Exp Clin Psychopharmacol* 2007;15(1):93-101.

1 BMJ Open

2 Protocol Submission

3 41 Rohsenow DJ, Marlatt GA. The balanced placebo design: Methodological considerations.  
4 *Addict Behav* 1981;6(2):107-22.

5  
6  
7  
8 42 Hull JG, Bond CF. Social and behavioral consequences of alcohol consumption and  
9 expectancy: a meta-analysis. *Psychol Bull* 1986;99(3):347-60.

10  
11  
12 43 Metrik J, Rohsenow DJ, Monti PM, et al. Effectiveness of a marijuana expectancy  
13 manipulation: Piloting the balanced-placebo design for marijuana. *Exp Clin Psychopharmacol*  
14 2009;17(4):217-25.

15  
16  
17  
18 44 Marlatt GA, Demming B, Reid JB. Loss of control drinking in alcoholics: an experimental  
19 analogue. *J Abnorm Psychol* 1973;81(3):233-41.

20  
21  
22  
23 45 Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and  
24 the reinforcing effects of stimulants in cocaine abusers. *J Neurosci* 2003;23(36):11461-68.

25  
26  
27  
28 46 Skarin K, Sulzer J. Placebo attribution in methadone patients. *Int J Addict* 1978;13(7):1049-  
29 59.

30  
31  
32 47 Colagiuri B, Schenk LA, Kessler MD, et al. The placebo effect: From concepts to genes.  
33 *Neuroscience* 2015;307:171-90.

34  
35  
36 48 CBS New York. "Seen at 11: Prescription Placebo." Online video clip. *YouTube* 6 Aug 2018.  
37 <https://www.youtube.com/watch?v=Jp14Lhl0T9w>

38  
39  
40  
41 49 Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy  
42 questionnaire. *J Behav Ther Exp Psychiatry* 2000;31(2):73-86.

43  
44  
45  
46 50 Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate  
47 withdrawal. *Am J Drug Alcohol Abuse* 1987;13(3):293-308.

48  
49  
50  
51 51 MacKillop J, Lisman SA. Effects of a context shift and multiple context extinction on  
52 reactivity to alcohol cues. *Exper Clin Psychopharm* 2008;16(4):322-31.

## BMJ Open

## Protocol Submission

52 Jobes ML, Aharonovich E, Epstein DH, et al. Effects of prereactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: A randomized study. *J Addict Med* 2015;9(6):491-98.

53 Longwell B, Kestler RJ, Cox TJ. Side effects in methadone patients: a survey of self-reported complaints. *Int J Addict* 1979;14(4):485-94.

54 Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum* 1996;39(6):681-5.

55 Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. *J Exper Psych Gen* 1999;28:78-87.

56 Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. *J Clin Psych* 1995;51:768-74.

57 Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS Scales. *J Pers Soc Psych* 1994;67(2):319-33.

58 Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychol Assess* 1995;7:524-32.

59 Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. *Psychiatry Res* 1989;28(2):193-213.

60 Krebs EE, Lorenz KA, Blair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 2009;24:733-8.

61 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81.

62 Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD. *J Psychoactive Drugs* 2018;50(2):167-76.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

63 Collins AB, Bluthenthal RN, Boyd J, et al. Harnessing the language of overdose prevention to  
advance evidence-based responses to the opioid crisis. *Int J Drug Policy* 2018;55:77-9.

64 Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson  
A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K,  
Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol  
items for clinical trials. *Ann Intern Med* 2013;158(3):200-207.

For peer review only

BMJ Open

Protocol Submission

**Acknowledgments:** Authors would like to acknowledge the following individuals for their contributions to study implementation: Zofia Kozak, Riti Kotamarti and Olivia Pettingill (assistance with study conduct); Ray Velencia (patient recruitment assistance); Denisha Pendleton (coordination of nurses' study roles); and the entire nursing and counseling staff of the University of Maryland Methadone Treatment Program. We would also like to acknowledge the contributions made by staff at the Center for Substance Abuse Research (CESAR), University of Maryland for the following contributions to the study: Jonathan Lewis and Julie Factor (assistance with instrument development, database development, data analysis); Lynn Wagner and Theresa Hippolyte in the Division of Forensic Toxicology at the Armed Forces Medical Examiner System (urinalyses). We used the SPIRIT checklist when writing our report<sup>64</sup>.

**Author Statement:** AMB and TOC conduct the study. AMB, TOC, ADG, EW, DHE, TJK and LC participated in the original design of the study protocol. SWH is responsible for placebo pill manufacture. DHE was responsible for the statistical design of the study. MW, ASB, EM and KRH helped to design or choose the study instruments, develop the database, and will conduct data analysis for the study. AMB wrote the first draft of the manuscript and all authors contributed revisions and approved the final manuscript.

**Funding:** This work was supported by the Foundation for the Science of the Therapeutic Experience (AMB), funds from the University of Maryland MPowering the State Opioid Use Disorders Initiative (AMB, EW, LC), and the Intramural Research Program of the National Institute on Drug Abuse of the National Institutes of Health (DHE). These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

**Competing interests:** None declared.

BMJ Open  
Protocol Submission

Table 1.

			Phase 1 (Weeks 1 and 2)		Phase 2 (Weeks 3+)		
			Meeting (and Day Number)				
Activity/ Instrument	CRF (Y/N)	Approx. Time to Complete	1	2	3	4	5
			Day 0	Day 14	Day 28	Day 56	Day 84
Verbal assessment of participant interest (intake coordinator)	N	1 minute	X				
Informed Consent Form	Y	5 minutes	X				
Evaluation to Sign Consent	Y	3 minutes	X				
HIPAA Authorization	Y	2 minutes	X				
Inclusion/Exclusion	Y	1 minute	X				
Study Script	Y	3 minutes	X				
Placebo Effect Video	Y	2 minutes	X				
Pill Information Sheet	Y	1 minute	X	X*	X*	X*	
Day 0 Expectancy Assessment	Y	<1 minute	X				
Past 2-Week Drug Use Assessment	Y	2-3 minutes	X	X	X	X	X
BIS/BAS	Y	8 minutes	X		X		X
Pain Catastrophizing Scale	Y	5 minutes	X		X		X
Pittsburgh Sleep	Y	6 minutes	X		X		X

BMJ Open  
Protocol Submission

Quality Index							
Cleveland Clinic Constipation Scoring	Y	5 minutes	X	X	X	X	X
WHO Quality of Life Assessment	Y	10 minutes	X	X	X	X	X
Craving Assessment	Y	<1 minute	X	X	X	X	X
SOWS	Y	5 minutes	X	X	X	X	X
OOWS	Y	5 minutes	X	X	X	X	X
Baseline Drug Use History	Y	10 minutes	X				
Randomization	Y	1 minute	X				
Order Form*	Y	1 minutes	X	X	X		
Urine Sample	Y	3 minutes	X	X	X	X	X
Payment Logs	Y	3 minutes	X	X	X	X	X
Phase I Compliance*	Y	<1 minute		X			
Methadone Side Effects Checklist	Y	5-7 minutes		X	X	X	X
MCQ	Y	4 minutes		X		X	X
BIS-11	Y	8 minutes		X			
Post-Baseline Drug Use History	Y	5 minutes		X	X	X	X
Phase II Compliance*	Y	<1 minute			X	X	X
Day 28 Expectancy Outcomes (group dependent)	Y	<1 minute				X	X
PEG Pain Scale	Y	2 minutes			X		
Exit Interview	Y	4 minutes					

Table 1. Assessment time line. \* Indicates assessments that were administered only to participants in Placebo Dose-Extension Group (PDE); CRF= case report form

1 BMJ Open

2 Protocol Submission

3 Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment

4 As Usual group; PDE = Placebo Dose Extension group

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment As Usual group; PDE = Placebo Dose Extension group

338x190mm (54 x 54 DPI)

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	26
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 26
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	1

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	26
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	26
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	6
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	8
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	8
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	8-9
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	9
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	10
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	11-12
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	12
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	12
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	11
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-15
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	27
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	15
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	15
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	10
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	10-11
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence until interventions are assigned	
2				
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	10-11
5	implementation			
6				
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	11
10				
11				
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
15	emergency			
16	unblinding			
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13-15, 27
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	16
32	retention			
33				
34				
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	16
39				
40				
41				
42				
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	16
47				
48				
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	16
52	analyses			
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	16
56	population and			
57	missing data			
58				
59				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	17
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	n/a
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	17
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	17
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	17
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9-10
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	16-17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	27
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

and disclosure of contractual agreements that limit such access for investigators

1				
2				
3				
4	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	n/a
5	trial care		compensation to those who suffer harm from trial	
6			participation	
7				
8				
9	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	17-18
10	trial results		results to participants, healthcare professionals, the public,	
11			and other relevant groups (eg, via publication, reporting in	
12			results databases, or other data sharing arrangements),	
13			including any publication restrictions	
14				
15				
16				
17	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	n/a
18	authorship		professional writers	
19				
20				
21	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	n/a
22	reproducible		participant-level dataset, and statistical code	
23	research			
24				
25				
26				
27	Informed consent	#32	Model consent form and other related documentation given	n/a
28	materials		to participants and authorised surrogates	
29				
30				
31	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	n/a
32			biological specimens for genetic or molecular analysis in the	
33			current trial and for future use in ancillary studies, if	
34			applicable	
35				
36				

37 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-  
 38 BY-ND 3.0. This checklist was completed on 10. September 2018 using <http://www.goodreports.org/>,  
 39 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60

# BMJ Open

## OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol for a randomized controlled clinical trial with methadone treatment

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026604.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Feb-2019
Complete List of Authors:	<p>Belcher, Annabelle; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment  Cole, Thomas; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment  Greenblatt, Aaron; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment  Hoag, Stephen; University of Maryland School of Pharmacy, Department of Pharmaceutical Sciences  Epstein, David; National Institute on Drug Abuse Intramural Research Program  Wagner, Michael; University of Maryland Center for Substance Abuse Research  Billing, Amy; University of Maryland Center for Substance Abuse Research  Massey, Ebonie; University of Maryland Center for Substance Abuse Research  Hamilton, Kristen; University of Maryland at College Park College of Behavioral and Social Sciences, Psychology  Kozak, Zofia; University of Maryland School of Medicine  Welsh, Christopher; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment  Weintraub, Eric; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment  Wickwire, Emerson; University of Maryland School of Medicine, Departments of Psychiatry and Medicine  Wish, Eric; University of Maryland Center for Substance Abuse Research  Kaptchuk, Ted; Harvard Medical School, Department of Global Health &amp; Social Medicine  Colloca, Luana; University of Maryland School of Nursing, Department of Pain and Translational Symptom Science</p>
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Mental health
Keywords:	Opioid Use Disorder, Methadone Maintenance, Placebo Effects, Opioids, Heroin Use Disorder, Substance misuse < PSYCHIATRY



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open

Protocol Submission

OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol  
for a randomized controlled clinical trial with methadone treatment

Annabelle M. Belcher<sup>1</sup>, Thomas O. Cole<sup>1</sup>, Aaron D. Greenblatt<sup>1</sup>, Stephen W. Hoag<sup>2</sup>, David H.  
Epstein<sup>3</sup>, Michael Wagner<sup>4</sup>, Amy S. Billing<sup>4</sup>, Ebonie Massey<sup>4</sup>, Kristen R. Hamilton<sup>5</sup>, Zofia  
Kozak<sup>6</sup>, Christopher J. Welsh<sup>1</sup>, Eric Weintraub<sup>1</sup>, Emerson M. Wickwire<sup>7</sup>, Eric D. Wish<sup>4</sup>, Ted J.  
Kaptchuk<sup>8</sup>, Luana Colloca<sup>9</sup>

<sup>1</sup>Division of Addiction Research and Treatment, Department of Psychiatry, University of  
Maryland School of Medicine, Baltimore, MD, USA

<sup>2</sup>Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy,  
Baltimore, MD, USA

<sup>3</sup>National Institute on Drug Abuse Intramural Research Program, National Institutes of Health,  
Baltimore, MD, USA

<sup>4</sup>Center for Substance Abuse Research, University of Maryland, College Park, MD, 20740, USA

<sup>5</sup>Department of Psychology, University of Maryland, College Park, MD, USA

<sup>6</sup>University of Maryland School of Medicine, Baltimore, MD, USA

<sup>7</sup>Departments of Psychiatry and Medicine, University of Maryland School of Medicine,  
Baltimore, MD, USA.

<sup>8</sup>Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School,  
Boston, MA, USA

<sup>9</sup>Department of Pain and Translational Symptom Science, University of Maryland School of  
Nursing, Baltimore, MD, USA

**Trial Sponsor and Correspondent:**

Annabelle (Mimi) M. Belcher, PhD: [abelcher@som.umaryland.edu](mailto:abelcher@som.umaryland.edu)

Division of Addiction Research and Treatment, Department of Psychiatry, University of  
Maryland School of Medicine, 110 S. Paca Street, Room 4N-101, University of Maryland,  
Baltimore, MD 21201 USA

410-328-6837 (O)

410-328-3693 (F)

**Word Count:** 5,180

1 BMJ Open  
2 Protocol Submission  
3  
4

5 **Keywords:** Opioid Use Disorder, Methadone Maintenance, Placebo Effect, Opioids, Heroin Use  
6 Disorder  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 BMJ Open  
2 Protocol Submission

3 **ABSTRACT**  
4  
5

6 **Introduction.** More than 2 million individuals in the United States have an Opioid Use Disorder  
7 (OUD). Methadone maintenance treatment is the gold standard of medication-assisted treatment  
8 for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory  
9 complications, among other side effects. These adverse effects make enhancing the effectiveness  
10 of lower doses of methadone an attractive therapeutic goal. Long recognized for its capacity to  
11 enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the  
12 placebo effect offers an as-yet untested avenue to such an enhancement. This approach is  
13 particularly compelling given that individuals with substance use disorder tend to have higher  
14 salience attribution, and may thereby be more sensitive to placebo effects. Our study combines  
15 two promising clinical methodologies—conditioning/dose-extension and open-label placebo—to  
16 investigate whether placebo effects can increase the effective potency of methadone in treatment-  
17 seeking OUD patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26

27  
28 **Methods and Analysis.** A total of 120 newly-enrolled treatment-seeking OUD patients will be  
29 randomly assigned to one of two different groups: either methadone plus daily placebo dose  
30 extension (PDE; treatment group), or methadone/Treatment as Usual (TAU; control).  
31  
32 Participants will meet with study team members five times over the course of three months of  
33 treatment with methadone (baseline, 2 weeks, and 1, 2 and 3 months post-baseline). Throughout  
34 this study time period, methadone dosages will be adjusted by an addiction clinician blind to  
35 patient assignment, per standard clinical methods. The primary outcome is methadone dose at  
36 three months. Secondary outcomes include self-report of drug use; 3-month urine toxicology  
37 screen results; and treatment retention. Exploratory outcomes include several environmental as  
38 well as personality factors associated with OUD and with propensity to demonstrate a placebo  
39 effect.  
40  
41  
42  
43  
44  
45  
46  
47

48 **Ethics and Dissemination.** Human subjects oversight for this study is provided by the  
49 University of Maryland, Baltimore and University of Maryland, College Park Institutional  
50 Review Boards. Additionally, the study protocol is reviewed annually by an independent Data  
51 and Safety Monitoring Board. Study results will be disseminated via research conference  
52 presentations and peer-reviewed publications.  
53  
54  
55  
56  
57

1 BMJ Open  
2 Protocol Submission

3 **Trial Registration Number.** ClinicalTrials.gov Identifier NCT02941809  
4  
5

6 **Strengths and limitations of this study**  
7

- 8
- 9 • This is the first randomized controlled trial designed to assess whether a combined  
10 conditioning paradigm and open-label placebo can be harnessed to enhance treatment  
11 outcomes in OUD.  
12
  - 13 • By employing an open-label transparent design, this study avoids the problematic ethical  
14 issues that would arise surrounding concealed or deceptive placebo administration, thus  
15 preserving patient autonomy and patient-clinician communication.  
16
  - 17 • Urine specimens will be tested for 240 substances, thus yielding a comprehensive picture  
18 of the opioids, new psychoactive drugs and pharmaceutical drugs recently used by  
19 patients.  
20
  - 21 • Additionally, a comprehensive patient self-report drug use instrument affords the unique  
22 opportunity to assess lifetime and current patterns of licit and illicit substance use  
23 (including prescription opioids), which can be used both to determine premorbid drug use  
24 patterns, as well as to assess the accuracy of patient self-reports of recent drug use.  
25
  - 26 • As a pilot proof-of-concept study designed to test open-label placebo conditioning on  
27 OUD treatment outcomes, this study does not incorporate closed-label (blind) treatment  
28 arms; we plan to address this limitation in future follow-up studies.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**INTRODUCTION**

Between 2001 and 2016, the number of opioid-related deaths in the United States increased by 345%, from 9,489 to 42,245<sup>1</sup>. The incredible surges in overdose deaths and in the prevalence of Opioid Use Disorder (OUD) have caused many federal and state agencies to identify this epidemic as one of the largest looming threats to public health today<sup>2</sup>.

Methadone maintenance treatment (MMT) is the most highly researched and evidence-based treatment for OUD, and has become a mainstay in treatment<sup>3</sup>. At appropriate doses, MMT is associated with significant improvements in a number of outcomes, including decreased drug use and crime, and increased positive health outcomes<sup>3-5</sup>. Perplexingly, there is great individual variability in MMT response. While some patients can fare well for years on end with low to moderate doses in the range of 30-60 mg/day<sup>6,7</sup>, many patients need much higher doses of methadone to control craving and drug-seeking behavior<sup>8,9</sup>. Unresolved medical debates on whether “more is better” provide no clarity on this issue, and with no generally accepted optimal dose prescription, clinicians titrate MMT dose to a subjective patient behavioral effect—a practice that sometimes translates to the prescription of very high doses of methadone<sup>7</sup>.

There are several reasons to give serious consideration to adjunctive treatments aimed at prevention of methadone dose escalation. For many patients, the high doses of methadone that seem to be needed for full therapeutic effect come at an unfortunate cost: side effects such as constipation, sedation, nausea, and sweating may be so great as to be a major determinant in treatment failures<sup>10</sup>. More alarmingly, higher methadone doses have been associated with risk factors for arrhythmias, such as QT interval prolongation and *Torsade de pointes*<sup>11</sup>, and reports of increasing methadone-related deaths have led to greater scrutiny of methadone dosing practices<sup>12,13</sup>. And from a patient perspective, an estimated 30% of MMT patients have severe anxiety related to MMT detoxification due to fear of withdrawal and relapse<sup>14,15</sup>: concerns that theoretically could be eased if those patients could be effectively treated at lower MMT doses. Collectively, these various issues and considerations provide ample rationale to explore options to increase the effectiveness of lower doses of methadone. Additionally, behavioral treatment adjuncts to MMT that offer promise for enhancing treatment outcomes (such as increasing

BMJ Open  
Protocol Submission

retention in treatment or decreasing risky drug use behavior while in treatment) deserve exploration.

One plausible adjunctive behavioral treatment involves placebo effects. Recent investigations have yielded greater appreciation of the therapeutic potential of harnessing placebo responses that otherwise occur naturally within the frame of medical treatment. Defined as the positive health outcomes derived from an inert substance or device used in the context of medical treatment<sup>16,17</sup>, placebo effects are guided by an individual's conscious or unconscious expectation of salubrious effects and can yield very powerful determinations of health outcomes across many different diseases and encounters<sup>16-19</sup>. Studies spanning two decades have shown that it is possible to condition the opioidergic system, the main neurotransmitter receptor system involved in addiction to drugs like heroin and prescription opioids. For example, placebo responses can be elicited by pairing morphine with placebo—an effect that is dependent on the strength of the association paradigm used to create the conditioned response<sup>20-23</sup>. Although groundbreaking, clinical practice translation of these studies is limited by methodology incorporating deception: researchers told participants that they would receive drug when in fact they were to receive placebo, and vice-versa.

We know of two promising strategies for ethically harnessing placebo effects. The first employs principles of Pavlovian conditioning<sup>24</sup>. By pairing placebo pills and clinical contextual cues (conditioned stimuli) with a physiologically active treatment (unconditioned stimuli), researchers have shown that medication dosages can be lowered without decreasing treatment efficacy<sup>25-29</sup>. This strategy is often referred to as placebo “dose-extension,” due to the fact that the placebo pill can be used to “extend” the efficacy of the medication with which it was paired, and subsequent placebo administration can produce therapeutic effects.

A second strategy is known as open-label placebo administration, in which the placebo is identified as such. Patients are usually told that “we know that placebos have powerful effects in double-blind trials and we want to test whether placebos work even when patients know that they are taking placebos”<sup>30,31</sup>. This approach has yielded positive results in a variety of somatic and pain-related conditions<sup>32-36</sup>. Researchers are proposing that open-label-induced placebo effects may involve aspects of error prediction processing<sup>30,37</sup>. But irrespective of mechanism, the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open

Protocol Submission

available data suggest that open-label methods work, and that they provide a solution to the ethical dilemma of patient-blinded placebo delivery.

In the context of substance use disorders, the placebo effect is interesting due to *prima facie* overlap in the genes and brain substrates implicated<sup>38</sup>. On a practical level, the case for harnessing placebo effects in addiction treatment is supported by a long line of research demonstrating that such effects are strong in drug-dependent individuals. For example, individuals dependent on nicotine<sup>39,40</sup>, alcohol<sup>41,42</sup> and marijuana<sup>43</sup> show differential drug consumption and/or subjective drug effects based on experimentally-manipulated expectations. In one of the earliest studies demonstrating this phenomenon, Marlatt showed that drinking behavior in alcohol-dependent subjects could be manipulated by beliefs concerning the alcohol content of the beverage: when expecting to sample a drink containing alcohol, subjects drank almost twice as much as those expecting to receive only non-alcoholic beverages<sup>44</sup>.

In a pivotal study, using a “balanced placebo” design, Volkow and colleagues<sup>45</sup> administered placebos to both cocaine abusers and non-drug abusing subjects and found a significant effect of modulating expectations; brain metabolic changes were about 50% greater when the subjects were informed about receiving drug, in comparison with the group of subjects who were informed about receiving placebo<sup>38,45</sup>. Intriguingly, methadone-treated OUD patients might be particularly sensitive to placebo effects relevant to their treatment<sup>46</sup>. To date, however, no group has explicitly tested whether these placebo effects could be used to improve medicalized addiction treatment outcomes. Further, no study has investigated the efficacy of either conditioning or open-label placebo strategies in a methadone maintenance context. This study uniquely combines two validated approaches to harnessing placebo effects in what we call an “open-label conditioning dose extension with placebo” paradigm, or, more succinctly, an “open-label placebo dose-extension (PDE)” paradigm.

**Objectives.** The broad goal of this study is to improve treatment outcomes for OUD patients who are newly enrolled in a daily outpatient MMT program. Specifically, we hypothesize that an open-label placebo dose-extension paradigm (PDE) will obviate higher-dose methadone treatment for a significant portion of new initiates and will thereby reduce methadone-associated side effects, with no concomitant diminution in outcomes such as self-reports and clinical



## BMJ Open Protocol Submission

observations of withdrawal, craving, and quality of life. We also hypothesize that the placebo intervention will enhance outcomes of methadone treatment; namely, we anticipate that treatment retention will be increased, and objective (urine toxicology results) and subjective (participant self-report) measures of drug use will be decreased, for participants assigned to the PDE arm.

We plan to recruit 120 participants and randomly assign them to one of two conditions: open-label placebo dose-extension (group PDE) plus methadone or methadone/Treatment as Usual (TAU). We will follow them for three months for a total of five in-person meetings (baseline, and two weeks, 1, 2 and 3 months post-baseline). For the first two weeks, we will implement principles of pharmacological conditioning<sup>24,47</sup> whereby placebo pills are temporally paired with the oral methadone hydrochloride solution that is provided to patients at the clinic (conditioning phase). Having established an association and contextualized the placebo as part of the therapeutic experience, placebos are then used as a dose extension (PDE) pill (dose extension phase, week 3 up to three months). Additionally, we are applying an open-label paradigm, giving participants information concerning the placebo pill in an honest and transparent manner. Our primary outcome is methadone dose three months after (baseline) entry into treatment; secondary outcomes include several measures of treatment success including comprehensive urine toxicology screens, self-reported drug use, and treatment retention. We are also capitalizing on this unique patient access opportunity to measure several personality and environmental factors associated with OUD, as well as factors associated with placebo response.

## **METHODS AND DATA ANALYSIS**

***Study Setting.*** Our ongoing study takes place at the University of Maryland Drug Treatment Center, an urban clinic located in West Baltimore, Maryland. The clinic is open 6 days a week (excluding holidays), and in addition to medication-assisted treatment, the clinic provides counseling and psychiatric services. The majority of our patients reside within one of five zip codes that immediately surround the clinic address, and present to the clinic either by referral or self-admission. Approximately 5 new patients are enrolled into MMT per week.

### ***Patient and Public Involvement***

1 BMJ Open  
2 Protocol Submission

3 Neither patients nor the public were involved in the design, recruitment or conduct of the study.  
4  
5

6 ***Patient Recruitment.*** Study participants will be 120 men and women OUD adults newly  
7 admitted to the UM Methadone Treatment Program (MTP). New patients are recruited on the  
8 first day of treatment in the clinic (Day 0). At the end of initial intake procedures of the first day,  
9 the Program Intake Coordinator asks new patients if they are interested in hearing information  
10 about a study that is testing a novel approach to enhancing methadone treatment, for which they  
11 would receive compensation. A member of the study team (either the P.I. [AMB] or the primary  
12 Research Coordinator [TOC]) makes contact with the intake coordinator to receive names of  
13 patients who are newly enrolled for MMT treatment and are willing to hear about the study.  
14  
15  
16  
17  
18  
19  
20

21 Patients who indicate their interest are brought to a private interview room located near the  
22 methadone dosing area, where they are screened for eligibility, informed about the study and  
23 conceptual basis of the placebo effect, and consented for participation. The study is registered  
24 with ClinicalTrials.gov Identifier NCT02941809, and has been approved by the University of  
25 Maryland Institutional Review Board and all procedures are performed in accordance with the  
26 relevant international and local guidelines and regulations for human research (UMB IRB  
27 Protocol # HP-00070829). A written informed consent is obtained from each study participant.  
28  
29  
30  
31  
32  
33

34 ***Eligibility Criteria.*** Participants are included in the study if they are newly enrolled (admission  
35 within the same day) in the MTP, have not had very recent experience with MMT in a clinic  
36 setting (within the past three weeks), and do not have any extenuating factors that would have a  
37 strong influence on clinical methadone dose determination. Inclusion criteria include: (i) adult  
38 (age 18 or over) and (ii) newly-admitted to the methadone treatment program. Exclusion factors  
39 include (i) pregnancy, (ii) treatment transfer (patients who have initiated methadone treatment  
40 course at another methadone treatment facility), (iii) hospital transfers (patients who initiated  
41 methadone treatment course in a hospital setting), or (iv) criminal justice system referrals.  
42  
43  
44  
45  
46  
47  
48

### 49 **Study Design and Procedures**

50  
51  
52 ***Randomization and Treatment Allocation.*** Prior to study inception, random treatment allocation  
53 was generated by an independent investigator, and consists of sequentially numbered opaque  
54 envelopes containing treatment assignments drawn from a computer-generated random number  
55  
56  
57

## BMJ Open

## Protocol Submission

1  
2  
3 sequence. These numbers are used to assign participants to either the open-label placebo dose-  
4 extension arm (PDE group) or a Treatment as Usual (TAU) arm, and two stacks of envelopes  
5 were created to ensure an even distribution of men and women (N=30/group/sex for a total of  
6  
7 120 random treatment allocations).  
8  
9

10  
11 Treatment allocation occurs after completion of the assessments. The investigator performs  
12 allocation by pulling an envelope from the top of the sex-specific stack. Following Day 0 study  
13 procedures, and just prior to the first dose of methadone at the treatment window, the  
14  
15 investigator conducts a treatment assignment “reveal,” opening the envelope and letting the  
16  
17 patient know the group to which s/he has been assigned.  
18  
19  
20

21 **Blinding.** Clinic staff are not directly involved with any aspect of the data collection that will be  
22 used to assess efficacy of the proposed PDE intervention. Treating physicians and nurse  
23 practitioners (NPs) make methadone dose adjustments both in face to face follow up encounters  
24 and during weekly interdisciplinary team meetings that include physicians, counselors, and  
25  
26 nurses. These dosing decisions are based on objective clinical assessments obtained outside of  
27  
28 the frame of the study, or, on occasion, after review of dosage change request submitted by a  
29  
30 patient or member of the clinical staff. Primary goals in increasing the methadone dose include  
31  
32 suppression of withdrawal symptoms, tempering of intrusive drug cravings, and agonist  
33  
34 blockade. Physicians and the NPs evaluate and document the relative risks and benefits of any  
35  
36 proposed dosage change, particularly taking into account over-sedation, drug-drug interactions,  
37  
38 cardiac side effects, and adherence to daily treatment. Treating physicians and NPs, including the  
39  
40 facility’s Medical Director (AG) are all blind to study enrollment and randomization. Given the  
41  
42 myriad variables that determine methadone dose changes, in the improbable event that a clinician  
43  
44 became unblinded to a patient’s treatment allocation (TAU or PDE), it is unlikely that this  
45  
46 knowledge would factor in the calculus of whether to make a dose adjustment, as the clinic’s  
47  
48 standard of care dictates that the participant’s well-being is the primary consideration in any  
49  
50 clinical course of action.

51  
52 As an open-label clinical trial, it is not possible to blind participants to their treatment allocation.  
53  
54 However, the scripted information that is delivered to the patients as part of the informed consent  
55  
56 procedures (detailed in the following section) do not guide participant expectations regarding the  
57

BMJ Open  
Protocol Submission

effects that the PDE intervention may have on methadone dose *per se*. Instead, participants are informed of the non-specific therapeutic benefits that a pharmacologically-conditioned placebo dose extension protocol may afford, with the primary outcome of interest (methadone dose) never explicitly mentioned to the participant. Additionally, because treatment allocation occurs only after Day 0 (baseline) assessments are complete, study team members are blind to treatment assignment for all of Day 0 procedures. Finally, data analysts are blind to treatment allocation.

**Script and Study Information Provided.** Patients are fully debriefed of all study procedures during an informed consent process. Participants are informed that their participation in the trial will have no effect on ongoing treatment afforded by the clinic, and further, that they have the right to withdraw from the study at any time with no impact on their clinical treatment. During and following consent, the notion is reinforced to the patients that the research study is “designed to investigate the efficacy of methadone treatment that is enhanced via inner healing processes using placebo effects.” As implemented in previous studies<sup>48</sup>, an IRB-approved script is used as a conversational guide to inform patients of the study rationale and procedures. This script has a positive framing, and describes in lay terms the science that underlies placebo effects and pharmacological conditioning, with an aim to facilitate the placebo response in a non-deceitful manner. Following the conversational reading of the script, the investigator asks the participant to view a video of a CBS New York News piece<sup>49</sup> that describes scientific studies of the successful use of the placebo phenomenon as a therapeutic intervention for Irritable Bowel Syndrome. The participant then completes the Day 0 (baseline) assessments (described below).

**Placebo Pills.** The placebo dose-extension (PDE) pill is produced by the University of Maryland School of Pharmacy Good Manufacturing Practice facility. The pills are composed of microcrystalline cellulose PH-102, magnesium stearate, and D&C Red 7 Ca Lake (inert chemicals and a food colorant, ingredients commonly contained in placebo pills manufactured by the pharmaceutical industry). PDE pills are stored in a locked medications cabinet maintained within the nurses’ station.

**Intervention: Daily PDE Pill Dispensing.** Following treatment assignment on Day 0, the investigator fills a placebo pill dispensing form indicating treatment assignment, and the patient is walked to the methadone dosing station. Placebo pills are stored and dispensed by the nursing

## BMJ Open

## Protocol Submission

staff of the MTP. If the patient is in group PDE, the investigator observes the participant taking the PDE pill. In Phase 1 of the study (first two weeks), participants assigned to group PDE are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), PDE participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. They are instructed to take this second pill twelve hours following the first pill, “at home, or wherever they may be.” Participants are asked to return the take-home pill bottle every day for refill. Circumstances may occur under which a participant may need to be withdrawn from the protocol, and include: not following instructions given by team members, or repeatedly missing appointments without contacting study staff. Adherence to the instructions to take the AM pill will be monitored by study team nursing staff.

***Urine Toxicology Screens.*** Urine drug screening occurs via two methods: (1) a point-of-care Quik-tox screen (11 panel; LabCorp) conducted by clinic staff, results of which are reported immediately, conducted at baseline and then at monthly (random) intervals post-baseline; (2) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) testing for a panel of more than 240 drugs, including new psychoactive substances, as well as other illicit and prescription drugs. All testing is conducted by the Division of Forensic Toxicology, Armed Forces Medical Examiner System and coordinated by the University of Maryland, College Park Center for Substance Abuse Research (CESAR) staff. Urine is collected from participants during each of the five meeting times, and the Quik-tox screen is conducted only on samples from meeting one (baseline); the LC/MS/MS testing is conducted on all samples (baseline and 2 weeks, 1, 2 and 3 months post-baseline screening).

***Primary Outcomes.*** The primary outcome is final methadone dose at the three-month time point. MTP clinicians adhere strictly to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) standards for medication-assisted treatment of OUD. Patients entering into treatment are given an initial evaluation that results in the prescription of an induction (initial dose  $\leq 30$  mg/d, followed by a gradual dose up-titration) and initial stabilization dose (typically 50-70 mg), which is usually reached by the third week of treatment. At two to three weeks, treatment progress is evaluated and an order is written to either continue or increase the initially-prescribed maintenance dose. As noted above, clinicians are blinded to the patient’s experimental-group assignment. In the MTP, approximately 75% of new patients who enter for

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

methadone treatment are given a recommendation to titrate up to a higher dose (personal communications with staff). We will be documenting the induction (starting), maintenance, as well as the ultimate stabilization dose. These data are obtained from patient charts documenting daily records of methadone dose dispensed.

**Secondary Outcomes.** Secondary outcomes include self-report of drug use, baseline, and 3-month urine screen results, and treatment retention. Self-report of drug use is assessed with an instrument developed by CESAR that asks lifetime and recent (past 24-48 hour) use of over 50 different licit and illicit drugs. Drug toxicology results of the urinalyses conducted by the Methadone Clinic (monthly random drug testing) and the independent research laboratory, as well as treatment retention (treatment days missed and take-home MMT) will be measured as secondary outcomes at baseline and at the 3-month time point.

**Exploratory Outcomes.** The unique longitudinal nature of this study allows us to assess several factors of interest, including personality factors associated with SUD and those associated with propensity to demonstrate a placebo effect. These self-report outcomes include scores on withdrawal and craving scales, quality of life, sleep patterns, placebo intervention expectation and compliance, as well as measures of impulsivity and catastrophizing. All assessments are administered by a member of our study team.

**Clinical Assessments** (see Table 1):

- *Baseline and Post-Baseline Drug Use History and Assessment* (CESAR): a comprehensive assessment of substance use history and treatment, environmental and psychosocial risk factors, and recent use of more than 30 commonly used licit and illicit drugs;
- *Adapted Credibility/Expectancy Questionnaires*<sup>50</sup>: a three-item assessment of participant beliefs that the PDE would improve their symptoms (Day 0), and a 3-4-item group-dependent assessment of participant beliefs that the PDE is helping or would help improve their symptoms (Days 14, 28, 56 and 84);
- *Subjective Opioid Withdrawal Scale* (SOWS)<sup>51</sup>: a 16-item patient self-report instrument to assess common subjective symptoms of craving and withdrawal;

## BMJ Open

## Protocol Submission

- *Objective Opioid Withdrawal Scale (OOWS)*<sup>51</sup>: a 13-item clinical assessment of physiological signs of withdrawal;
- *Craving Assessment*<sup>52,53</sup>: an adapted one-item visual-analog scale;
- *World Health Organization Quality of Life Scale – Brief (WHOQOL-BREF)*: a 26-item assessment of life satisfaction;
- *Compliance*: a visual-analog scale assessing compliance with instructions to take the PDE pill;
- *Past 2-Week Substance Use*: self-reported frequency of use of four broad classes of drugs;
- *Methadone Symptom Severity Checklist*<sup>54</sup>: symptom severity of 38 commonly-reported methadone treatment-associated side effects;
- *Cleveland Clinic Constipation Scoring System*<sup>55</sup>: an 8-item scale of constipation severity

***Psychological Measurements***

- *Monetary Choice Questionnaire (MCQ)*<sup>56</sup>: a 27-item assessment of delay discounting that asks participants to make hypothetical choices between a smaller-sooner amount of money available today or a larger-later amount of money available after a delay;
- *Barratt Impulsivity Scale, version 11 (BIS-11)*<sup>57</sup>: a 30-item assessment that yields information regarding several three facets of trait impulsivity (i.e., attentional impulsivity, motor impulsivity, and non-planning impulsivity), wherein participants indicate on a four point Likert-like scale the extent to which each of 30 items describes their overall behavior;
- *Behavioral Inhibition/Activation System Scales (BIS/BAS)*<sup>58</sup>: a 24-item assessment of behavioral inhibition (BIS) and approach (BAS), wherein participants indicate on a four point Likert-like scale the extent to which each of 24 items describes their behavioral style;
- *Pain Catastrophizing Scale (PCS)*<sup>59</sup>: a 13-item assessment of how pain is subjectively experienced, wherein participants indicate on a four point Likert-like scale the extent to which each of the 13 items describe the thoughts and feelings they have when they are experiencing pain;

## BMJ Open

## Protocol Submission

- *Pittsburgh Sleep Quality Index (PSQI)*<sup>60</sup>: a 9-item assessment of sleep satisfaction;
- *PEG Pain Screening Tool*<sup>61</sup>: a 3-item assessment of pain intensity and interference;
- *Exit Survey*: a 7-item quantitative and qualitative assessment of how the PDE pill was experienced by participants and their thoughts about their experience participating in the study.

A detailed time line of all outcome assessments is provided in Table 1.

**Sample Size Calculation.** We anticipate that dose escalations will be recommended at dose evaluation (approximately three weeks following entry into treatment) for approximately 70% of participants in the TAU control group. With 60 participants per group, we will have power of .80 to detect a difference between groups if the corresponding rate in the intervention group is 44% or lower (i.e., a maximum of 26/60 participants), using a Fisher exact test with a two-tailed alpha of .05. This is a medium-to-large effect, equivalent to an odds ratio of 3.03 or a Cohen's *d* of .61.

For our non-inferiority tests on outcome indicators, power depends on the rate of occurrence (for dichotomous outcomes) and on the sample standard deviation (for continuous outcomes). Thus, if a dichotomous outcome (such as reports of withdrawal) occurs in 15% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 19%, using a one-sided 95% confidence interval, as is appropriate for a non-inferiority test. If reports of withdrawal occur in 5% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 12%, using a one-sided 95% confidence interval. Similarly, if scores on a measure of withdrawal severity have a standard deviation of 0.5 with no observed difference in means between groups, we will have power of .90 to conclude that the real difference in means is no greater than .27 standard deviations, using a one-sided 95% confidence interval. If the scores have a standard deviation of 0.8 with no observed difference in means between groups, we will have power of .90 to conclude that the real difference in means is no greater than .43 standard deviations, using a one-sided 95% confidence interval. To help ensure that we obtain usable data from 120 completed participants (60 per group), we plan to screen and enroll 240 participants. Attrition within the first three months of treatment at the MTP is not heavy, but we want to take a conservative approach to the possibility of noncompliance with study measures and procedures.



## BMJ Open

## Protocol Submission

**Data Analysis.** We will use a between-group (PDE vs. TAU) comparison of the proportion of patients who move up to a higher methadone dose, and a comparison of scores or counts on all other measures. We will make these comparisons with an exact test unless demographic comparisons of the two groups suggest that we need to control for potential confounding co-variables such as sex, race, age, or baseline indicators of addiction severity, in which case we will use multiple logistic regression. We will also test for non-inferiority on the following outcome measures: (1) frequency of positive drug testing (urine and self-report); (2) SOWS score; (3) OOWS score; (4) Craving score; (5) WHOQOL-BREF; (6) days in treatment; (7) methadone side effects checklist; (8) Constipation Severity Score. The analytic method will be determined by the distribution of the data on the outcome measure (e.g., generalized linear mixed models for frequency of positive urine drug tests, and general linear mixed models for questionnaire scores), but the hypothesis of non-inferiority will always be tested by comparison of one-sided 95% confidence intervals for the parameter estimates.

**Anticipated Outcomes.** We anticipate that a substantial proportion of patients in the PDE group will not need to be escalated to the higher doses of methadone (see Figure 1). We also expect that patients in this group will have clinical improvements at least as good as those in the control group, in terms of decreased craving, withdrawal, drug use and urine-positive drug tests, increased scores on a quality of life assessment, and treatment retention at the three-month (84-day) time point—with fewer side effects from methadone. Finally, we anticipate that primary and secondary outcomes will scale with both expectancy and compliance.

**Data Collection: Retention, Quality Management and Storage.** Participants are given an appointment card that serves as a reminder of the next date that they are to meet with study staff. Additionally, a member of the study team calls participants one day prior to the designated meeting day to remind them of their appointment. Data are collected in an in-person meeting on paper for each instrument. Following the meeting, data are recorded electronically in an *ad hoc* project created in RedCAP<sup>62</sup>, a secure data collection and management application hosted at the University of Maryland, Baltimore. Once recorded, data are verified by a secondary independent observer and subsequently locked to prevent changes from being made. Missing data due to missed meetings are coded as incomplete. The resulting database is imported into SPSS and logical consistency checks are conducted and addressed, and missing values designated. Data

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

collected on paper are de-identified with a Study ID number, and stored in a locked cabinet in an off-site location. And electronic identifying information will be password-protected on an encrypted, HIPAA-compliant drive, and all study authors will have access to verified, cleaned and de-identified data sets.

**Data Monitoring.** The study is reviewed annually by an independent Data Safety and Monitoring Board. Progress reports include reporting of adverse events, updates on enrollment, raw data reporting, and any outcomes and preliminary analyses.

**Unanticipated/Adverse/Reportable New Information Event Reporting.** Although the likelihood of an adverse event is exceedingly unlikely, participants in the PDE group will receive a pill instruction handout (attached under "relevant materials" above). This handout will contain explicit information on who to contact in case of an adverse event situation. The Methadone Clinic is staffed daily by a work force of doctors, nurses and clinical counselors who are specifically trained to work with this population of individuals suffering from substance use disorder. In the unlikely event that a participant shows signs of crisis (e.g. heightened anxiety) due to discomfort with any aspect of the assessments, a counselor or doctor on the floor will be engaged to intervene promptly.

**Ethics and dissemination:** All activities associated with this protocol are conducted in full compliance with current University of Maryland, Baltimore and University of Maryland, College Park Human Research Protection Programs and Institutional Review Board policies and procedures while maintaining compliance with federal regulations. This protocol is approved and is active with IRBs of both universities. Written informed consent is obtained from every participant. Important protocol modifications will be communicated to relevant members of the research team *via* Collaborative Institutional Comprehensive Evaluation of Research Online (CICERO), the University of Maryland School of Medicine's Research Evaluation Portal. Any results from this trial (publications, conference presentations) will be published in peer-reviewed journals and conference proceedings.

## DISCUSSION

BMJ Open  
Protocol Submission

To our knowledge, this is the first randomized, controlled clinical trial that implements methods of inducing ethically-appropriate placebo responses in an addiction treatment context. The findings obtained will provide crucial pilot data concerning the effectiveness of placebo interventions implemented in the context of OUD treatment. Additionally, understanding the capacity for pharmacological conditioning to impact outcomes in this patient population could have very significant clinical and translational implications, and could provide strong justification for its use in the clinic as a method of increasing the ratio of benefits to side effects in MMT.

In addition to exploring the therapeutic potential of a harnessed placebo response, through comprehensive urine screen analysis, this ongoing clinical trial will yield important information regarding the precise types of drugs that are being consumed in a West Baltimore neighborhood, currently “Ground Zero” in the nation’s current opioid epidemic<sup>63</sup>. In a time of rapid changes in the synthetic drugs available on the street, patients often report having no awareness of the substances they have ingested (personal communications, AMB, EW, ADG, 2018). Our comprehensive urinalysis will help inform current trends in use, and help realize the scope of compounds contained in street drugs. Additionally, patient self-report of lifetime history of drug use will afford a unique opportunity to understand drug use patterns (particularly, prescription opioid use) that may have predated use of other opioids such as heroin.

This clinical trial study is designed to explore whether open-label placebo can be integrated into treatment with salubrious effects. Because the goal is to move the needle very quickly to enhance medical addiction treatment, we wanted to take the simplest approach to obtaining an answer on whether placebo pills might be a useful tool in this arsenal. As such, we chose to restrict ourselves to a two-arm design (PDE vs. TAU). A limitation of this approach, however, is that we will not be able to produce data on how patients would respond to placebo pills delivered blindly: in other words, traditional placebo effects invoked using non-transparent methods. We plan to address this gap in future follow-up studies.

As numbers of new individuals afflicted with OUD continue to rise, the NIH has called on the scientific community to deliver effective and sustainable solutions to stave this formidable public health challenge<sup>64</sup>. Medication-Assisted Treatment is the only treatment strategy with a

1 BMJ Open

2 Protocol Submission

3 scientific basis, and the treatment of choice for OUD, endorsed fully by the medical community.  
4  
5 Harnessing a potentially effective placebo response to enhance methadone treatment of OUD is  
6 responsive to this NIH call, with the additional boon of very low financial burden and risk to  
7 patients. If our RCT outcome is successful, it would represent an important first step towards a  
8 safe, inexpensive and quick-to-launch adjunct to methadone that could feasibly change front-line  
9 addiction medicine treatment of OUD.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 BMJ Open  
2 Protocol Submission

3 **REFERENCES**

4  
5  
6 1 Gomes T, Tadrous M, Mamdani MM, et al. The Burden of Opioid-Related Mortality in the  
7 United States. *JAMA Network Open* 2018;1(2):e180217.

8  
9 doi:10.1001/jamanetworkopen.2018.0217

10  
11  
12 2 U.S. Department of Health and Human Services (HHS). Office of the Surgeon General, Facing  
13 Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health.

14  
15 Washington, DC: *HHS* 2016.

16  
17  
18 3 Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies—tackling the opioid-  
19 overdose epidemic. *N Engl J Med* 2014;370:2063–66.

20  
21  
22 4 Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid  
23 replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009;3:CD002209.

24  
25  
26 5 Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and  
27 future directions. *Harv Rev Psychiatry* 2015;23(2):63-75.

28  
29  
30 6 Maremmani I, Pacini M, Lubrano S, et al. When “enough” is still not “enough”: Effectiveness  
31 of high-dose methadone in the treatment of heroin addiction. *Heroin Add & Rel Clin Probl*  
32 2003;5:17–32

33  
34  
35 7 Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual  
36 opioid-dependent patients. *PLoS Med* 2006;3(3):e80.

37  
38  
39 8 Strain EC, Stitzer ML, Liebson IA, et al. Methadone dose and treatment outcome. *Drug and*  
40 *Alcohol Dependence* 1993;33:105-17.

41  
42  
43 9 Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of  
44 higher-dose methadone. *J Psychoactive Drugs* 1999;31(2):95-102.

## BMJ Open

## Protocol Submission

10 Adams RG, Capel WC, Bloom WA, et al. Heroin addicts on methadone replacement: a study of dropouts. *Int J Addict* 1971;6(2):269-77.

11 Martin JA, Campbell A, Killip T, et al. QT Interval Screening in Methadone Maintenance Treatment: Report of a SAMHSA Expert Panel. *J Addict Dis* 2011;30(4):283-306.

12 Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain* 2014;15(4):321-37.

13 Weimer MB, Chou R. Research gaps on methadone harms and comparative harms: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. *J Pain* 2014;15(4):366-76.

14 Milby JB, Gurwitch RH, Wiebe DJ, et al. Prevalence and diagnostic reliability of methadone maintenance detoxification fear. *Am J Psychiatry* 1986;143(6):739-43.

15 Eklund C, Hiltunen AJ, Melin L, et al. Abstinence fear in methadone maintenance withdrawal: a possible obstacle for getting off methadone. *Subst Use Misuse* 1997;32(6):779-92.

16 Colloca, L. The Placebo Effect in Pain Therapies. *Annu Rev Pharmacol Toxicol* 2019;59:191-211.

17 Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. *N Engl J Med* 2015;373(1):8-9.

18 Colloca L, Flaten MA, Meissner K. (Eds.). *Placebo and pain: from bench to bedside*. Academic Press 2013.

19 Colloca L, Klinger R, Flor H, et al. Placebo analgesia: psychological and neurobiological mechanisms. *Pain* 2013;154(4):511-4.

## BMJ Open

## Protocol Submission

20 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. *J*

*Neurosci* 1999;19(1):484-94.

21 Benedetti F, Pollo A, Lopiano L, et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. *J Neurosci* 2003;23(10):4315-23.

22 Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. *Neuroscience* 2007;147(2):260-71.

23 Benedetti F. Placebo and Endogenous mechanisms of analgesia. *Handb Exp Pharmacol* 2007;177:393-413.

24 Colloca L, Enck P, DeGrazia D. Relieving pain using dose-extending placebos: a scoping review. *Pain* 2016;157(8):1590-98.

25 Ader R, Mercurio MG, Walton J, et al. Conditioned pharmacotherapeutic effects: a preliminary study. *Psychosom Med* 2010;72(2):192-97.

26 Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. *Child Care Health Dev* 2008;34(1):104-10.

27 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? *J Dev Behav Pediatr* 2010;31(5):369-75.

28 Perlis M, Grandner M, Zee J, et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. *Sleep Med* 2015;16(9):1160-68.

29 Kirchhof J, Petrakova L, Brinkhoff A, et al. Learned immunosuppressive placebo responses in renal transplant patients. *Proc Natl Acad Sci U S A* 2018;115(16):4223-27.

1 BMJ Open

2 Protocol Submission

3 30 Kaptchuk TJ. Open-label placebo: Reflections on a research agenda. *Perspect Biol Med*  
4 2018; 20:311-34.  
5  
6

7  
8 31 Kaptchuk TJ, Miller FG. Open-label placebo: Can honestly prescribed placebos evoke  
9 meaningful therapeutic benefits? *BMJ* 2018; 363:k3889.  
10  
11

12 32 Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized  
13 controlled trial in irritable bowel syndrome. *PLoS One* 2010;5(12):e15591.  
14  
15

16  
17 33 Carvalho C, Caetano JM, Cunha L, et al. Open-label placebo treatment in chronic low back  
18 pain: a randomized controlled trial. *Pain* 2016;157(12):2766-2772.  
19  
20

21  
22 34 Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes  
23 the outcome of episodic migraine attacks. *Sci Transl Med* 2014;6(218):218ra5.  
24  
25

26  
27 35 Schaefer M, Harke R, Denke C. Open-Label Placebos Improve Symptoms in Allergic  
28 Rhinitis: A Randomized Controlled Trial. *Psychother Psychosom* 2016;85(6):373-374.  
29  
30

31 36 Hoenemeyer TW, Kaptchuk TJ, Mehta TS, et al. Open-Label Placebo Treatment for Cancer-  
32 Related Fatigue: A Randomized-Controlled Clinical Trial. *Sci Rep* 2018;8(1):2784.  
33  
34

35  
36 37 Ongaro G, Kaptchuk TJ. Symptom perception, placebo effects and the Bayesian brain. *Pain*  
37 2018 (in press).  
38  
39

40  
41 38 Belcher AM, Ferré S, Martinez PE, et al. Role of placebo effects in pain and neuropsychiatric  
42 disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2018;87(Pt B):298-306.  
43  
44

45  
46 39 Juliano LM, Brandon TH. Effects of nicotine dose, instructional set, and outcome  
47 expectancies on the subjective effects of smoking in the presence of a stressor. *J Abnorm*  
48 *Psychol* 2002;111(1):88-97.  
49  
50

51  
52 40 Kelemen WL, Kaighobadi F. Expectancy and pharmacology influence the subjective effects  
53 of nicotine in a balanced-placebo design. *Exp Clin Psychopharmacol* 2007;15(1):93-101.  
54  
55



## BMJ Open

## Protocol Submission

41 Rohsenow DJ, Marlatt GA. The balanced placebo design: Methodological considerations. *Addict Behav* 1981;6(2):107-22.

42 Hull JG, Bond CF. Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. *Psychol Bull* 1986;99(3):347-60.

43 Metrik J, Rohsenow DJ, Monti PM, et al. Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. *Exp Clin Psychopharmacol* 2009;17(4):217-25.

44 Marlatt GA, Demming B, Reid JB. Loss of control drinking in alcoholics: an experimental analogue. *J Abnorm Psychol* 1973;81(3):233-41.

45 Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. *J Neurosci* 2003;23(36):11461-68.

46 Skarin K, Sulzer J. Placebo attribution in methadone patients. *Int J Addict* 1978;13(7):1049-59.

47 Colagiuri B, Schenk LA, Kessler MD, et al. The placebo effect: From concepts to genes. *Neuroscience* 2015;307:171-90.

48 Kaptchuk TJ, Miller FG. Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits? *BMJ* 2018;363:k3889.

49 CBS New York. "Seen at 11: Prescription Placebo." Online video clip. *YouTube* 6 Aug 2018. <https://www.youtube.com/watch?v=Jp14Lhl0T9w>

50 Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31(2):73-86.

51 Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. *Am J Drug Alcohol Abuse* 1987;13(3):293-308.

52 MacKillop J, Lisman SA. Effects of a context shift and multiple context extinction on reactivity to alcohol cues. *Exper Clin Psychopharm* 2008;16(4):322-31.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

53 Jobes ML, Aharonovich E, Epstein DH, et al. Effects of preroactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: A randomized study. *J Addict Med* 2015;9(6):491-98.

54 Longwell B, Kestler RJ, Cox TJ. Side effects in methadone patients: a survey of self-reported complaints. *Int J Addict* 1979;14(4):485-94.

55 Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum* 1996;39(6):681-5.

56 Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. *J Exper Psych Gen* 1999;28:78-87.

57 Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. *J Clin Psych* 1995;51:768-74.

58 Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS Scales. *J Pers Soc Psych* 1994;67(2):319-33.

59 Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychol Assess* 1995;7:524-32.

60 Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. *Psychiatry Res* 1989;28(2):193-213.

61 Krebs EE, Lorenz KA, Blair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 2009;24:733-8.

62 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81.

1 BMJ Open

2 Protocol Submission

3 63 Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug  
4 in Baltimore, MD. *J Psychoactive Drugs* 2018;50(2):167-76.  
5

6  
7  
8 64 Collins AB, Bluthenthal RN, Boyd J, et al. Harnessing the language of overdose prevention to  
9 advance evidence-based responses to the opioid crisis. *Int J Drug Policy* 2018;55:77-9.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 BMJ Open  
2 Protocol Submission

3 **Acknowledgments:** Authors would like to acknowledge the following individuals for their  
4 contributions to study implementation: Riti Kotamarti and Olivia Pettingill (assistance with study  
5 conduct); Ray Velencia (patient recruitment assistance); Denisha Pendleton (coordination of  
6 nurses' study roles); and the entire nursing and counseling staff of the University of Maryland  
7 Methadone Treatment Program. We would also like to acknowledge the contributions made by  
8 staff at the Center for Substance Abuse Research (CESAR), University of Maryland for the  
9 following contributions to the study: Jonathan Lewis and Julie Factor (assistance with instrument  
10 development, database development, data analysis); Lynn Wagner and Theresa Hippolyte in the  
11 Division of Forensic Toxicology at the Armed Forces Medical Examiner System (urinalyses).  
12 We used the SPIRIT checklist when writing our report.  
13  
14  
15  
16  
17  
18  
19  
20

21 **Author Statement:** AMB and TOC conduct the study. AMB, TOC, ADG, EWe, DHE, ZK,  
22 CJW, EWi, TJK and LC participated in the original design of the study protocol. SWH is  
23 responsible for placebo pill manufacture. DHE was responsible for the statistical design of the  
24 study. MW, ASB, EM, EWi, EMW and KRH helped to design or choose the study instruments,  
25 develop the database, and will conduct data analysis for the study. AMB wrote the first draft of  
26 the manuscript and all authors contributed revisions and approved the final manuscript.  
27  
28  
29  
30  
31  
32

33 **Funding:** This work was supported by the Foundation for the Science of the Therapeutic  
34 Experience (AMB), funds from the University of Maryland MPowering the State Opioid Use  
35 Disorders Initiative (AMB, EWi, LC), and the Intramural Research Program of the National  
36 Institute on Drug Abuse of the National Institutes of Health (DHE). These funding sources had  
37 no role in the design of this study and will not have any role during its execution, analyses,  
38 interpretation of the data, or decision to submit results.  
39  
40  
41  
42  
43

44 **Competing interests:** None declared.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

Table 1.

			Phase 1 (Weeks 1 and 2)		Phase 2 (Weeks 3+)		
			Meeting (and Day Number)				
Activity/ Instrument	CRF (Y/N)	Approx. Time to Complete	1	2	3	4	5
			Day 0	Day 14	Day 28	Day 56	Day 84
Verbal assessment of participant interest (intake coordinator)	N	1 minute	X				
Informed Consent Form	Y	5 minutes	X				
Evaluation to Sign Consent	Y	3 minutes	X				
HIPAA Authorization	Y	2 minutes	X				
Inclusion/Exclusion	Y	1 minute	X				
Study Script	Y	3 minutes	X				
Placebo Effect Video	Y	2 minutes	X				
Pill Information Sheet	Y	1 minute	X	X*	X*	X*	
Day 0 Expectancy Assessment	Y	<1 minute	X				
Past 2-Week Drug Use Assessment	Y	2-3 minutes	X	X	X	X	X
BIS/BAS	Y	8 minutes	X		X		X
Pain Catastrophizing Scale	Y	5 minutes	X		X		X

BMJ Open  
Protocol Submission

Pittsburgh Sleep Quality Index	Y	6 minutes	X		X		X
Cleveland Clinic Constipation Scoring	Y	5 minutes	X	X	X	X	X
WHO Quality of Life Assessment	Y	10 minutes	X	X	X	X	X
Craving Assessment	Y	<1 minute	X	X	X	X	X
SOWS	Y	5 minutes	X	X	X	X	X
OOWS	Y	5 minutes	X	X	X	X	X
Baseline Drug Use History	Y	10 minutes	X				
Randomization	Y	1 minute	X				
Order Form*	Y	1 minutes	X	X	X		
Urine Sample	Y	3 minutes	X	X	X	X	X
Payment Logs	Y	3 minutes	X	X	X	X	X
Phase I Compliance*	Y	<1 minute		X			
Methadone Side Effects Checklist	Y	5-7 minutes		X	X	X	X
MCQ	Y	4 minutes		X		X	X
BIS-11	Y	8 minutes		X			
Post-Baseline Drug Use History	Y	5 minutes		X	X	X	X
Phase II Compliance*	Y	<1 minute			X	X	X
Day 28 Expectancy Outcomes (group dependent)	Y	<1 minute				X	X
PEG Pain Scale	Y	2 minutes			X		
Exit Interview	Y	4 minutes					

1 BMJ Open  
2 Protocol Submission

3 Table 1. Assessment time line. \* Indicates assessments that were administered only to  
4 participants in Placebo Dose-Extension Group (PDE); CRF= case report form  
5  
6

7  
8 Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment  
9 As Usual group; PDE = Placebo Dose Extension group  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Hypothetical Methadone Treatment Course and Expected Outcome




Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment As Usual group; PDE = Placebo Dose Extension group



# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	26
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 26
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	1

1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	26
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	26
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	6
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	8
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	8
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	8-9
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	9
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	10
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	11-12
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	12
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	12
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	11
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-15
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	27
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	15
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	15
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	10
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	10-11
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	10-11
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	11
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	13-15,
21			and other trial data, including any related processes to	27
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	16
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	16
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	16
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	16
52	analyses		adjusted analyses)	
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	16
56	population and		adherence (eg, as randomised analysis), and any statistical	
57	missing data		methods to handle missing data (eg, multiple imputation)	
58				
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	17
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	n/a
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	17
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	17
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	17
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9-10
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	16-17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	27
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

		and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17-18
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 10. September 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

# BMJ Open

## OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol for a randomized controlled clinical trial with methadone treatment

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026604.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Apr-2019
Complete List of Authors:	<p>Belcher, Annabelle; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Cole, Thomas; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Greenblatt, Aaron; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Hoag, Stephen; University of Maryland School of Pharmacy, Department of Pharmaceutical Sciences            Epstein, David; National Institute on Drug Abuse Intramural Research Program            Wagner, Michael; University of Maryland Center for Substance Abuse Research            Billing, Amy; University of Maryland Center for Substance Abuse Research            Massey, Ebonie; University of Maryland Center for Substance Abuse Research            Hamilton, Kristen; University of Maryland at College Park College of Behavioral and Social Sciences, Psychology            Kozak, Zofia; University of Maryland School of Medicine            Welsh, Christopher; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Weintraub, Eric; University of Maryland School of Medicine, Department of Psychiatry, Division of Addiction Research and Treatment            Wickwire, Emerson; University of Maryland School of Medicine, Departments of Psychiatry and Medicine            Wish, Eric; University of Maryland Center for Substance Abuse Research            Kaptchuk, Ted; Harvard Medical School, Department of Global Health &amp; Social Medicine            Colloca, Luana; University of Maryland School of Nursing, Department of Pain and Translational Symptom Science</p>
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Mental health
Keywords:	Opioid Use Disorder, Methadone Maintenance, Placebo Effects, Opioids, Heroin Use Disorder, Substance misuse < PSYCHIATRY

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open

Protocol Submission

OPEN-LABEL DOSE-EXTENDING PLACEBOS FOR OPIOID USE DISORDER: A protocol  
for a randomized controlled clinical trial with methadone treatment

Annabelle M. Belcher<sup>1</sup>, Thomas O. Cole<sup>1</sup>, Aaron D. Greenblatt<sup>1</sup>, Stephen W. Hoag<sup>2</sup>, David H.  
Epstein<sup>3</sup>, Michael Wagner<sup>4</sup>, Amy S. Billing<sup>4</sup>, Ebonie Massey<sup>4</sup>, Kristen R. Hamilton<sup>5</sup>, Zofia  
Kozak<sup>6</sup>, Christopher J. Welsh<sup>1</sup>, Eric Weintraub<sup>1</sup>, Emerson M. Wickwire<sup>7</sup>, Eric D. Wish<sup>4</sup>, Ted J.  
Kaptchuk<sup>8</sup>, Luana Colloca<sup>9</sup>

<sup>1</sup>Division of Addiction Research and Treatment, Department of Psychiatry, University of  
Maryland School of Medicine, Baltimore, MD, USA

<sup>2</sup>Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy,  
Baltimore, MD, USA

<sup>3</sup>National Institute on Drug Abuse Intramural Research Program, National Institutes of Health,  
Baltimore, MD, USA

<sup>4</sup>Center for Substance Abuse Research, University of Maryland, College Park, MD, 20740, USA

<sup>5</sup>Department of Psychology, University of Maryland, College Park, MD, USA

<sup>6</sup>University of Maryland School of Medicine, Baltimore, MD, USA

<sup>7</sup>Departments of Psychiatry and Medicine, University of Maryland School of Medicine,  
Baltimore, MD, USA.

<sup>8</sup>Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School,  
Boston, MA, USA

<sup>9</sup>Department of Pain and Translational Symptom Science, University of Maryland School of  
Nursing, Baltimore, MD, USA

**Trial Sponsor and Correspondent:**

Annabelle (Mimi) M. Belcher, PhD: [abelcher@som.umaryland.edu](mailto:abelcher@som.umaryland.edu)

Division of Addiction Research and Treatment, Department of Psychiatry, University of  
Maryland School of Medicine, 110 S. Paca Street, Room 4N-101, University of Maryland,  
Baltimore, MD 21201 USA

410-328-6837 (O)

410-328-3693 (F)

**Word Count:** 5,180

1 BMJ Open  
2 Protocol Submission  
3  
4

5 **Keywords:** Opioid Use Disorder, Methadone Maintenance, Placebo Effect, Opioids, Heroin Use  
6 Disorder  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 BMJ Open  
2 Protocol Submission

3 **ABSTRACT**  
4  
5

6 **Introduction.** More than 2 million individuals in the United States have an Opioid Use Disorder  
7 (OUD). Methadone maintenance treatment is the gold standard of medication-based treatment  
8 for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory  
9 complications, among other side effects. These adverse effects make enhancing the effectiveness  
10 of lower doses of methadone an attractive therapeutic goal. Long recognized for its capacity to  
11 enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the  
12 placebo effect offers an as-yet untested avenue to such an enhancement. This approach is  
13 particularly compelling given that individuals with substance use disorder tend to have higher  
14 salience attribution and may thereby be more sensitive to placebo effects. Our study combines  
15 two promising clinical methodologies—conditioning/dose-extension and open-label placebo—to  
16 investigate whether placebo effects can increase the effective potency of methadone in treatment-  
17 seeking OUD patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 **Methods and Analysis.** A total of 120 newly-enrolled treatment-seeking OUD patients will be  
29 randomly assigned to one of two different groups: either methadone plus daily placebo dose  
30 extension (PDE; treatment group), or methadone/Treatment as Usual (TAU; control).  
31 Participants will meet with study team members five times over the course of three months of  
32 treatment with methadone (baseline, 2 weeks, and 1, 2 and 3 months post-baseline). Throughout  
33 this study time period, methadone dosages will be adjusted by an addiction clinician blind to  
34 patient assignment, per standard clinical methods. The primary outcome is methadone dose at  
35 three months. Secondary outcomes include self-report of drug use; 3-month urine toxicology  
36 screen results; and treatment retention. Exploratory outcomes include several environmental as  
37 well as personality factors associated with OUD and with propensity to demonstrate a placebo  
38 effect.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 **Ethics and Dissemination.** Human subjects oversight for this study is provided by the  
49 University of Maryland, Baltimore and University of Maryland, College Park Institutional  
50 Review Boards. Additionally, the study protocol is reviewed annually by an independent Data  
51 and Safety Monitoring Board. Study results will be disseminated via research conference  
52 presentations and peer-reviewed publications.  
53  
54  
55  
56  
57

1 BMJ Open  
2 Protocol Submission

3 **Trial Registration Number.** ClinicalTrials.gov Identifier NCT02941809  
4  
5

6 **Strengths and limitations of this study**  
7

- 8
- 9 • This is the first randomized controlled trial designed to assess whether a combined  
10 conditioning paradigm and open-label placebo can be harnessed to enhance treatment  
11 outcomes in OUD.  
12
  - 13 • By employing an open-label transparent design, this study avoids the problematic ethical  
14 issues that would arise surrounding concealed or deceptive placebo administration, thus  
15 preserving patient autonomy and patient-clinician communication.  
16
  - 17 • Urine specimens will be tested for 240 substances, thus yielding a comprehensive picture  
18 of the opioids, new psychoactive drugs and pharmaceutical drugs recently used by  
19 patients.  
20
  - 21 • Additionally, a comprehensive patient self-report drug use instrument affords the unique  
22 opportunity to assess lifetime and current patterns of licit and illicit substance use  
23 (including prescription opioids), which can be used both to determine premorbid drug use  
24 patterns, as well as to assess the accuracy of patient self-reports of recent drug use.  
25
  - 26 • As a pilot proof-of-concept study designed to test open-label placebo conditioning on  
27 OUD treatment outcomes, this study does not incorporate closed-label (blind) treatment  
28 arms; we plan to address this limitation in future follow-up studies.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**INTRODUCTION**

Between 2001 and 2016, the number of opioid-related deaths in the United States increased by 345%, from 9,489 to 42,245<sup>1</sup>. The incredible surges in overdose deaths and in the prevalence of Opioid Use Disorder (OUD) have caused many federal and state agencies to identify this epidemic as one of the largest looming threats to public health today<sup>2</sup>.

Methadone maintenance treatment (MMT) is the most highly researched and evidence-based treatment for OUD and has become a mainstay in treatment<sup>3</sup>. At appropriate doses, MMT is associated with significant improvements in several outcomes, including decreased drug use and crime, and increased positive health outcomes<sup>3-5</sup>. Perplexingly, there is great individual variability in MMT response. While some patients can fare well for years on end with low to moderate doses in the range of 30-60 mg/day<sup>6,7</sup>, many patients need much higher doses of methadone to control craving and drug-seeking behavior<sup>8,9</sup>. Unresolved medical debates on whether “more is better” provide no clarity on this issue, and with no generally accepted optimal dose prescription, clinicians titrate MMT dose to a subjective patient behavioral effect—a practice that sometimes translates to the prescription of very high doses of methadone<sup>7</sup>.

There are several reasons to give serious consideration to adjunctive treatments aimed at prevention of methadone dose escalation. For many patients, the high doses of methadone that seem to be needed for full therapeutic effect come at an unfortunate cost: side effects such as constipation, sedation, nausea, and sweating may be so great as to be a major determinant in treatment failures<sup>10</sup>. More alarmingly, higher methadone doses have been associated with risk factors for arrhythmias, such as QT interval prolongation and *Torsade de pointes*<sup>11</sup>, and reports of increasing methadone-related deaths have led to greater scrutiny of methadone dosing practices<sup>12,13</sup>. And from a patient perspective, an estimated 30% of MMT patients have severe anxiety related to MMT detoxification due to fear of withdrawal and relapse<sup>14,15</sup>: concerns that theoretically could be eased if those patients could be effectively treated at lower MMT doses. Collectively, these various issues and considerations provide ample rationale to explore options to increase the effectiveness of lower doses of methadone.

BMJ Open  
Protocol Submission

One plausible adjunctive behavioral treatment involves placebo effects. Recent investigations have yielded greater appreciation of the therapeutic potential of harnessing placebo responses that otherwise occur naturally within the frame of medical treatment. Defined as the positive health outcomes derived from an inert substance or device used in the context of medical treatment<sup>16,17</sup>, placebo effects are guided by an individual's conscious or unconscious expectation of salubrious effects and can yield very powerful determinations of health outcomes across many different diseases and encounters<sup>16-19</sup>. Studies spanning two decades have shown that it is possible to condition the opioidergic system, the main neurotransmitter receptor system involved in addiction to drugs like heroin and prescription opioids. For example, placebo responses can be elicited by pairing morphine with placebo—an effect that is dependent on the strength of the association paradigm used to create the conditioned response<sup>20-23</sup>. Although groundbreaking, clinical practice translation of these studies is limited by methodology incorporating deception: researchers told participants that they would receive drug when in fact they were to receive placebo, and vice-versa.

We know of two promising strategies for ethically harnessing placebo effects. The first employs principles of Pavlovian conditioning<sup>24</sup>. By pairing placebo pills and clinical contextual cues (conditioned stimuli) with a physiologically active treatment (unconditioned stimuli), researchers have shown that medication dosages can be lowered without decreasing treatment efficacy<sup>25-29</sup>. This strategy is often referred to as placebo “dose-extension,” due to the fact that the placebo pill can be used to “extend” the efficacy of the medication with which it was paired, and subsequent placebo administration can produce therapeutic effects.

A second strategy is known as open-label placebo administration, in which the placebo is identified as such. Patients are usually told that “we know that placebos have powerful effects in double-blind trials and we want to test whether placebos work even when patients know that they are taking placebos”<sup>30,31</sup>. This approach has yielded positive results in a variety of somatic and pain-related conditions<sup>32-36</sup>. Researchers are proposing that open-label-induced placebo effects may involve aspects of error prediction processing<sup>30,37</sup>. But irrespective of mechanism, the available data suggest that open-label methods work, and that they provide a solution to the ethical dilemma of patient-blinded placebo delivery.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

In the context of substance use disorders, the placebo effect is interesting due to *prima facie* overlap in the genes and brain substrates implicated<sup>38</sup>. On a practical level, the case for harnessing placebo effects in addiction treatment is supported by a long line of research demonstrating that such effects are strong in drug-dependent individuals. For example, individuals dependent on nicotine<sup>39,40</sup>, alcohol<sup>41,42</sup> and marijuana<sup>43</sup> show differential drug consumption and/or subjective drug effects based on experimentally-manipulated expectations. In one of the earliest studies demonstrating this phenomenon, Marlatt showed that drinking behavior in alcohol-dependent subjects could be manipulated by beliefs concerning the alcohol content of the beverage: when expecting to sample a drink containing alcohol, subjects drank almost twice as much as those expecting to receive only non-alcoholic beverages<sup>44</sup>.

In a pivotal study, using a “balanced placebo” design, Volkow and colleagues<sup>45</sup> administered placebos to both cocaine abusers and non-drug abusing subjects and found a significant effect of modulating expectations; brain metabolic changes were about 50% greater when the subjects were informed about receiving drug, in comparison with the group of subjects who were informed about receiving placebo<sup>38,45</sup>. Intriguingly, methadone-treated OUD patients might be particularly sensitive to placebo effects relevant to their treatment<sup>46</sup>. To date, however, no group has explicitly tested whether these placebo effects could be used to improve medicalized addiction treatment outcomes. Further, no study has investigated the efficacy of either conditioning or open-label placebo strategies in a methadone maintenance context. This study uniquely combines two validated approaches to harnessing placebo effects in what we call an “open-label conditioning dose extension with placebo” paradigm, or, more succinctly, an “open-label placebo dose-extension (PDE)” paradigm.

**Objectives.** The broad goal of this study is to improve treatment outcomes for OUD patients who are newly enrolled in a daily outpatient MMT program. Specifically, we hypothesize that an open-label placebo dose-extension paradigm (PDE) will obviate higher-dose methadone treatment for a significant portion of new initiates and will thereby reduce methadone-associated side effects, with no concomitant change in outcomes such as treatment retention, drug use, self-reports and clinical observations of withdrawal, craving or quality of life.

## BMJ Open

## Protocol Submission

We plan to recruit 120 participants and randomly assign them to one of two conditions: open-label placebo dose-extension (group PDE) plus methadone or methadone/Treatment as Usual (TAU). We will follow them for three months for a total of five in-person meetings (baseline, and two weeks, 1, 2 and 3 months post-baseline). For the first two weeks, we will implement principles of pharmacological conditioning<sup>24,47</sup> whereby placebo pills are temporally paired with the oral methadone hydrochloride solution that is provided to patients at the clinic (conditioning phase). Having established an association and contextualized the placebo as part of the therapeutic experience, placebos are then used as a dose extension (PDE) pill (dose extension phase, week 3 up to three months). Additionally, we are applying an open-label paradigm, giving participants information concerning the placebo pill in an honest and transparent manner. Our primary outcome is methadone dose three months after (baseline) entry into treatment; secondary outcomes include several measures of treatment success including comprehensive urine toxicology screens, self-reported drug use, and treatment retention. We are also capitalizing on this unique patient access opportunity to measure several personality and environmental factors associated with OUD, as well as factors associated with placebo response.

**METHODS AND DATA ANALYSIS**

**Study Setting.** Our ongoing study takes place at the University of Maryland Drug Treatment Center, an urban clinic located in West Baltimore, Maryland. The clinic is open 6 days a week (excluding holidays), and in addition to medication-based treatment, the clinic provides counseling and psychiatric services. The majority of our patients reside within one of five zip codes that immediately surround the clinic address, and present to the clinic either by referral or self-admission. Approximately 5 new patients are enrolled into MMT per week.

**Patient and Public Involvement**

Neither patients nor the public were involved in the design, recruitment or conduct of the study.

**Patient Recruitment.** Study participants will be 120 men and women OUD adults newly admitted to the UM Methadone Treatment Program (MTP). New patients are recruited on the first day of treatment in the clinic (Day 0). At the end of initial intake procedures of the first day, the Program Intake Coordinator asks new patients if they are interested in hearing information



## BMJ Open

## Protocol Submission

about a study that is testing a novel approach to enhancing methadone treatment, for which they would receive compensation. A member of the study team (either the P.I. [AMB] or the primary Research Coordinator [TOC]) contacts the intake coordinator to receive names of patients who are newly enrolled for MMT treatment and are willing to hear about the study.

Patients who indicate their interest are brought to a private interview room located near the methadone dosing area, where they are screened for eligibility, informed about the study and conceptual basis of the placebo effect, and consented for participation. The study is registered with ClinicalTrials.gov Identifier NCT02941809 and has been approved by the University of Maryland Institutional Review Board. All procedures are performed in accordance with the relevant international and local guidelines and regulations for human research (UMB IRB Protocol # HP-00070829). A written informed consent is obtained from each study participant.

***Eligibility Criteria.*** Participants are included in the study if they are newly enrolled (admission within the same day) in the MTP, have not had very recent experience with MMT in a clinic setting (within the past three weeks), and do not have any extenuating factors that would have a strong influence on clinical methadone dose determination. Inclusion criteria include: (i) adult (age 18 or over) and (ii) newly-admitted to the methadone treatment program. Exclusion factors include (i) pregnancy, (ii) treatment transfer (patients who have initiated methadone treatment course at another methadone treatment facility), (iii) hospital transfers (patients who initiated methadone treatment course in a hospital setting), or (iv) criminal justice system referrals.

**Study Design and Procedures**

***Randomization and Treatment Allocation.*** Prior to study inception, random treatment allocation was generated by an independent investigator, and consists of sequentially numbered opaque envelopes containing treatment assignments drawn from a computer-generated random number sequence. These numbers are used to assign participants to either the open-label placebo dose-extension arm (PDE group) or a Treatment as Usual (TAU) arm, and two stacks of envelopes were created to ensure an even distribution of men and women (N=30/group/sex for a total of 120 random treatment allocations).

## BMJ Open

## Protocol Submission

Treatment allocation occurs after completion of the assessments. The investigator performs allocation by pulling an envelope from the top of the sex-specific stack. Following Day 0 study procedures, and just prior to the first dose of methadone at the treatment window, the investigator conducts a treatment assignment “reveal,” opening the envelope and letting the patient know the group to which s/he has been assigned.

**Blinding.** Clinic staff are independent of the research study implementation. Correspondingly, members of the study team responsible for administration of assessments, delivery of placebo pills or data analysis play no role in dose increase/decrease determinations. Methadone dose adjustments are made based on two criteria: (1) scores on a validated subjective withdrawal symptom checklist and (2) treatment team consensus. (1) The Subjective Opioid Withdrawal Scoring (SOWS) system is an assessment of the severity of symptoms of withdrawal and is delivered outside of the study frame (the SOWS measurements that are obtained as part of the baseline, 2-week and 1-, 2- and 3-month study team meetings are distinct, kept separate from the clinical SOWS assessment for dose change determination). All patients in the clinic are asked to submit their responses on this checklist at a time point corresponding with their achievement of an initial stabilization dose, generally 2-4 weeks post-entry into treatment. This assessment is considered as one factor in dose change determinations. (2) Treatment teams meet weekly to discuss individual patients’ progress, and consensus must be obtained between the treating physician, the counselor and the nurse practitioner (NP) to recommend a dose increase. Primary goals in increasing the methadone dose include suppression of withdrawal symptoms, tempering of intrusive drug cravings, and agonist blockade. Physicians and the NP evaluate and document the relative risks and benefits of any proposed dosage change, with attention paid to several factors including over-sedation, drug-drug interactions, cardiac side effects, and adherence to daily treatment. Treating physicians and the NP, including the facility’s Medical Director (AG) are all blind to study enrollment and randomization. Patient study participation is not discussed during treatment team meetings, and the counselors, NP and physicians are asked not to probe patients about their involvement and experience with the study. Thus, it is unlikely that a physician or NP would become unblinded to treatment allocation. Regardless, given the myriad variables that determine methadone dose changes, it is unlikely that this knowledge would factor in the calculus of whether to make a dose adjustment, as the clinic’s standard of care dictates that

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

the participant's well-being is the primary consideration in any clinical course of action. If, however, a physician or the NP becomes unblinded to a patient's study treatment allocation, they are asked to communicate that to a member of the study team.

As an open-label clinical trial, it is not possible to blind participants to their treatment allocation. However, the scripted information that is delivered to the patients as part of the informed consent procedures (detailed in the following section) do not guide participant expectations regarding the effects that the PDE intervention may have on methadone dose *per se*. Instead, participants are informed of the non-specific therapeutic benefits that a pharmacologically-conditioned placebo dose extension protocol may afford, with the primary outcome of interest (methadone dose) never explicitly mentioned to the participant. Additionally, because treatment allocation occurs only after Day 0 (baseline) assessments are complete, study team members are blind to treatment assignment for all of Day 0 procedures. Finally, data analysts are blind to treatment allocation.

***Script and Study Information Provided.*** Patients are fully debriefed of all study procedures during an informed consent process. Participants are informed that their participation in the trial will have no effect on ongoing treatment afforded by the clinic, and further, that they have the right to withdraw from the study at any time with no impact on their clinical treatment. During and following consent, the notion is reinforced to the patients that the research study is “designed to investigate the efficacy of methadone treatment that is enhanced via inner healing processes using placebo effects.” As implemented in previous studies<sup>48</sup>, an IRB-approved script is used as a conversational guide to inform patients of the study rationale and procedures. This script has a positive framing and describes in lay terms the science that underlies placebo effects and pharmacological conditioning, with an aim to facilitate the placebo response in a non-deceitful manner. Following the conversational reading of the script, the investigator asks the participant to view a video of a CBS New York News piece<sup>49</sup> that describes scientific studies of the successful use of the placebo phenomenon as a therapeutic intervention for Irritable Bowel Syndrome. The participant then completes the Day 0 (baseline) assessments (described below).

***Placebo Pills.*** The placebo dose-extension (PDE) pill is produced by the University of Maryland School of Pharmacy Good Manufacturing Practice facility. The pills are composed of microcrystalline cellulose PH-102, magnesium stearate, and D&C Red 7 Ca Lake (inert

BMJ Open  
Protocol Submission

chemicals and a food colorant, ingredients commonly contained in placebo pills manufactured by the pharmaceutical industry). PDE pills are stored in a locked medications cabinet maintained within the nurses' station.

***Intervention: Daily PDE Pill Dispensing.*** Following treatment assignment on Day 0, the investigator fills a placebo pill dispensing form indicating treatment assignment, and the patient is walked to the methadone dosing station. Placebo pills are stored and dispensed by the nursing staff of the MTP. If the patient is in group PDE, the investigator observes the participant taking the PDE pill. In Phase 1 of the study (first two weeks), participants assigned to group PDE are given one pill, to be taken concurrently with the methadone. In Phase 2 (3 weeks up to 3 months), PDE participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. They are instructed to take this second pill twelve hours following the first pill, "at home, or wherever they may be." Participants are asked to return the take-home pill bottle every day for refill. Circumstances may occur under which a participant may need to be withdrawn from the protocol and include: not following instructions given by team members, or repeatedly missing appointments without contacting study staff. Adherence to the instructions to take the AM pill will be monitored by study team nursing staff.

***Urine Toxicology Screens.*** Urine drug screening occurs via two methods: (1) a point-of-care Quik-tox screen (11 panel; LabCorp) conducted by clinic staff, results of which are reported immediately, conducted at baseline and then at monthly (random) intervals post-baseline; (2) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) testing for a panel of more than 240 drugs, including new psychoactive substances, as well as other illicit and prescription drugs. All testing is conducted by the Division of Forensic Toxicology, Armed Forces Medical Examiner System and coordinated by the University of Maryland, College Park Center for Substance Abuse Research (CESAR) staff. Urine is collected from participants during each of the five meeting times, and the Quik-tox screen is conducted only on samples from meeting one (baseline); the LC/MS/MS testing is conducted on all samples (baseline and 2 weeks, 1, 2 and 3 months post-baseline screening).

***Primary Outcomes.*** The primary outcome is final methadone dose at the three-month time point. MTP clinicians adhere strictly to the Substance Abuse and Mental Health Services

## BMJ Open

## Protocol Submission

Administration's (SAMHSA) standards for medication-based treatment of OUD. Patients entering treatment are given an initial evaluation that results in the prescription of an induction (initial dose  $\leq 30$  mg/d, followed by a gradual dose up-titration) and initial stabilization dose (typically 50-70 mg), which is usually reached by the third week of treatment. At two to three weeks, treatment progress is evaluated, and an order is written to either continue or increase the initially-prescribed maintenance dose. As noted above, clinicians are blinded to the patient's experimental-group assignment. In the MTP, approximately 75% of new patients who enter for methadone treatment are given a recommendation to titrate up to a higher dose (personal communications with staff). We will be documenting the induction (starting), maintenance, as well as the ultimate stabilization dose. These data are obtained from patient charts documenting daily records of methadone dose dispensed.

**Secondary Outcomes.** Secondary outcomes include self-report of drug use, baseline, and 3-month urine screen results, and treatment retention. Self-report of drug use is assessed with an instrument developed by CESAR that asks lifetime and recent (past 24-48 hour) use of over 50 different licit and illicit drugs. Drug toxicology results of the urinalyses conducted by the Methadone Clinic (monthly random drug testing) and the independent research laboratory, as well as treatment retention (treatment days missed and take-home MMT) will be measured as secondary outcomes at baseline and at the 3-month time point. Other self-report outcomes include scores on withdrawal and craving scales, quality of life and sleep patterns.

**Exploratory Outcomes.** The unique longitudinal nature of this study allows us to assess several factors of interest, including personality factors associated with SUD and those associated with propensity to demonstrate a placebo effect, placebo intervention expectation and compliance, as well as measures of impulsivity and catastrophizing. All assessments are administered by a member of our study team.

**Clinical Assessments** (see Table 1):

- *Baseline and Post-Baseline Drug Use History and Assessment (CESAR):* a comprehensive assessment of substance use history and treatment, environmental and

## BMJ Open

## Protocol Submission

psychosocial risk factors, and recent use of more than 30 commonly used licit and illicit drugs;

- *Adapted Credibility/Expectancy Questionnaires*<sup>50</sup>: a three-item assessment of participant beliefs that the PDE would improve their symptoms (Day 0), and a 3-4-item group-dependent assessment of participant beliefs that the PDE is helping or would help improve their symptoms (Days 14, 28, 56 and 84);
- *Subjective Opioid Withdrawal Scale (SOWS)*<sup>51</sup>: a 16-item patient self-report instrument to assess common subjective symptoms of craving and withdrawal;
- *Objective Opioid Withdrawal Scale (OOWS)*<sup>51</sup>: a 13-item clinical assessment of physiological signs of withdrawal;
- *Craving Assessment*<sup>52,53</sup>: an adapted one-item visual-analog scale;
- *World Health Organization Quality of Life Scale – Brief (WHOQOL-BREF)*: a 26-item assessment of life satisfaction;
- *Compliance*: a visual-analog scale assessing compliance with instructions to take the PDE pill;
- *Past 2-Week Substance Use*: self-reported frequency of use of four broad classes of drugs;
- *Methadone Symptom Severity Checklist*<sup>54</sup>: symptom severity of 38 commonly-reported methadone treatment-associated side effects;
- *Cleveland Clinic Constipation Scoring System*<sup>55</sup>: an 8-item scale of constipation severity

**Psychological Measurements**

- *Monetary Choice Questionnaire (MCQ)*<sup>56</sup>: a 27-item assessment of delay discounting that asks participants to make hypothetical choices between a smaller-sooner amount of money available today or a larger-later amount of money available after a delay;
- *Barratt Impulsivity Scale, version 11 (BIS-11)*<sup>57</sup>: a 30-item assessment that yields information regarding several three facets of trait impulsivity (i.e., attentional impulsivity, motor impulsivity, and non-planning impulsivity), wherein participants indicate on a four point Likert-like scale the extent to which each of 30 items describes their overall behavior;

## BMJ Open

## Protocol Submission

- *Behavioral Inhibition/Activation System Scales (BIS/BAS)*<sup>58</sup>: a 24-item assessment of behavioral inhibition (BIS) and approach (BAS), wherein participants indicate on a four point Likert-like scale the extent to which each of 24 items describes their behavioral style;
- *Pain Catastrophizing Scale (PCS)*<sup>59</sup>: a 13-item assessment of how pain is subjectively experienced, wherein participants indicate on a four point Likert-like scale the extent to which each of the 13 items describe the thoughts and feelings they have when they are experiencing pain;
- *Pittsburgh Sleep Quality Index (PSQI)*<sup>60</sup>: a 9-item assessment of sleep satisfaction;
- *PEG Pain Screening Tool*<sup>61</sup>: a 3-item assessment of pain intensity and interference;
- *Exit Survey*: a 7-item quantitative and qualitative assessment of how the PDE pill was experienced by participants and their thoughts about their experience participating in the study.

A detailed time line of all outcome assessments is provided in Table 1.

**Sample Size Calculation.** We anticipate that dose escalations will be recommended at dose evaluation (approximately three weeks following entry into treatment) for approximately 70% of participants in the TAU control group. With 60 participants per group, we will have power of .80 to detect a difference between groups if the corresponding rate in the intervention group is 44% or lower (i.e., a maximum of 26/60 participants), using a Fisher exact test with a two-tailed alpha of .05. This is a medium-to-large effect, equivalent to an odds ratio of 3.03 or a Cohen's *d* of .61.

For our non-inferiority tests on outcome indicators, power depends on the rate of occurrence (for dichotomous outcomes) and on the sample standard deviation (for continuous outcomes). Thus, if a dichotomous outcome (such as reports of withdrawal) occurs in 15% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 19%, using a one-sided 95% confidence interval, as is appropriate for a non-inferiority test. If reports of withdrawal occur in 5% of each group, we will have power of .90 to conclude that the real difference in proportions is no greater than 12%, using a one-sided 95% confidence interval. Similarly, if scores on a measure of withdrawal severity have a standard deviation of 0.5 with no observed difference in means between groups, we will have power of .90 to conclude that the

## BMJ Open

## Protocol Submission

1  
2  
3 real difference in means is no greater than .27 standard deviations, using a one-sided 95%  
4 confidence interval. If the scores have a standard deviation of 0.8 with no observed difference in  
5 means between groups, we will have power of .90 to conclude that the real difference in means is  
6 no greater than .43 standard deviations, using a one-sided 95% confidence interval. To help  
7 ensure that we obtain usable data from 120 completed participants (60 per group), we plan to  
8 screen and enroll 240 participants. Attrition within the first three months of treatment at the MTP  
9 is not heavy, but we want to take a conservative approach to the possibility of noncompliance  
10 with study measures and procedures.  
11  
12  
13  
14  
15  
16  
17

18 **Data Analysis.** We will use a between-group (PDE vs. TAU) comparison of the proportion of  
19 patients who move up to a higher methadone dose, and a comparison of scores or counts on all  
20 other measures. We will make these comparisons with an exact test unless demographic  
21 comparisons of the two groups suggest that we need to control for potential confounding co-  
22 variables such as sex, race, age, or baseline indicators of addiction severity, in which case we  
23 will use multiple logistic regression. We will also test for non-inferiority on the following  
24 outcome measures: (1) frequency of positive drug testing (urine and self-report); (2) SOWS  
25 score; (3) OOWS score; (4) Craving score; (5) WHOQOL-BREF; (6) days in treatment; (7)  
26 methadone side effects checklist; (8) Constipation Severity Score. The analytic method will be  
27 determined by the distribution of the data on the outcome measure (e.g., generalized linear mixed  
28 models for frequency of positive urine drug tests, and general linear mixed models for  
29 questionnaire scores), but the hypothesis of non-inferiority will always be tested by comparison  
30 of one-sided 95% confidence intervals for the parameter estimates.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 **Anticipated Outcomes.** We anticipate that a substantial proportion of patients in the PDE group  
43 will not need to be escalated to the higher doses of methadone (see Figure 1). We also expect  
44 that patients in this group will have clinical improvements at least as good as those in the control  
45 group, in terms of decreased craving, withdrawal, drug use and urine-positive drug tests,  
46 increased scores on a quality of life assessment, and treatment retention at the three-month (84-  
47 day) time point—with fewer side effects from methadone. Finally, we anticipate that primary  
48 and secondary outcomes will scale with both expectancy and compliance.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1 BMJ Open  
2 Protocol Submission

3 **Data Collection: Retention, Quality Management and Storage.** Participants are given an  
4 appointment card that serves as a reminder of the next date that they are to meet with study staff.  
5 Additionally, a member of the study team calls participants one day prior to the designated  
6 meeting day to remind them of their appointment. Data are collected in an in-person meeting on  
7 paper for each instrument. Following the meeting, data are recorded electronically in an *ad hoc*  
8 project created in RedCAP<sup>62</sup>, a secure data collection and management application hosted at the  
9 University of Maryland, Baltimore. Once recorded, data are verified by a secondary independent  
10 observer and subsequently locked to prevent changes from being made. Missing data due to  
11 missed meetings are coded as incomplete. The resulting database is imported into SPSS and  
12 logical consistency checks are conducted and addressed, and missing values designated. Data  
13 collected on paper are de-identified with a Study ID number and stored in a locked cabinet in an  
14 off-site location. And electronic identifying information will be password-protected on an  
15 encrypted, HIPAA-compliant drive, and all study authors will have access to verified, cleaned  
16 and de-identified data sets.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 **Data Monitoring.** The study is reviewed annually by an independent Data Safety and Monitoring  
29 Board. Progress reports include reporting of adverse events, updates on enrollment, raw data  
30 reporting, and any outcomes and preliminary analyses.

31  
32  
33  
34  
35 **Unanticipated/Adverse/Reportable New Information Event Reporting.** Although the likelihood  
36 of an adverse event is exceedingly unlikely, participants in the PDE group will receive a pill  
37 instruction handout (attached under "relevant materials" above). This handout will contain  
38 explicit information on who to contact in case of an adverse event situation. The Methadone  
39 Clinic is staffed daily by a work force of doctors, nurses and clinical counselors who are  
40 specifically trained to work with this population of individuals suffering from substance use  
41 disorder. In the unlikely event that a participant shows signs of crisis (e.g. heightened anxiety)  
42 due to discomfort with any aspect of the assessments, a counselor or doctor on the floor will be  
43 engaged to intervene promptly.

44  
45  
46  
47  
48  
49  
50  
51 **Ethics and dissemination:** All activities associated with this protocol are conducted in full  
52 compliance with current University of Maryland, Baltimore and University of Maryland, College  
53 Park Human Research Protection Programs and Institutional Review Board policies and  
54

BMJ Open  
Protocol Submission

procedures while maintaining compliance with federal regulations. This protocol is approved and is active with IRBs of both universities. Written informed consent is obtained from every participant. Important protocol modifications will be communicated to relevant members of the research team *via* Collaborative Institutional Comprehensive Evaluation of Research Online (CICERO), the University of Maryland School of Medicine's Research Evaluation Portal. Any results from this trial (publications, conference presentations) will be published in peer-reviewed journals and conference proceedings.

## DISCUSSION

To our knowledge, this is the first randomized, controlled clinical trial that implements methods of inducing ethically-appropriate placebo responses in an addiction treatment context. The findings obtained will provide crucial pilot data concerning the effectiveness of placebo interventions implemented in the context of OUD treatment. Additionally, understanding the capacity for pharmacological conditioning to impact outcomes in this patient population could have very significant clinical and translational implications, and could provide strong justification for its use in the clinic as a method of increasing the ratio of benefits to side effects in MMT.

In addition to exploring the therapeutic potential of a harnessed placebo response, through comprehensive urine screen analysis, this ongoing clinical trial will yield important information regarding the precise types of drugs that are being consumed in a West Baltimore neighborhood, currently "Ground Zero" in the nation's current opioid epidemic<sup>63</sup>. In a time of rapid changes in the synthetic drugs available on the street, patients often report having no awareness of the substances they have ingested (personal communications, AMB, EWe, ADG, 2018). Our comprehensive urinalysis will help inform current trends in use and will help realize the scope of compounds contained in street drugs. Additionally, patient self-report of lifetime history of drug use will afford a unique opportunity to understand drug use patterns (particularly, prescription opioid use) that may have predated use of other opioids such as heroin.

This clinical trial study is designed to explore whether open-label placebo can be integrated into treatment with salubrious effects. Because the goal is to move the needle very

## BMJ Open

## Protocol Submission

1  
2  
3 quickly to enhance medical addiction treatment, we wanted to take the simplest approach to  
4 obtaining an answer on whether placebo pills might be a useful tool in this arsenal. As such, we  
5 chose to restrict ourselves to a two-arm design (PDE vs. TAU). A limitation of this approach,  
6 however, is that we will not be able to produce data on how patients would respond to placebo  
7 pills delivered blindly: in other words, traditional placebo effects invoked using non-transparent  
8 methods. We plan to address this gap in future follow-up studies.  
9  
10  
11  
12  
13

14  
15 As numbers of new individuals afflicted with OUD continue to rise, the NIH has called  
16 on the scientific community to deliver effective and sustainable solutions to stave this formidable  
17 public health challenge<sup>64</sup>. Medication-Based Treatment is the only treatment strategy with a  
18 scientific basis, and the treatment of choice for OUD, endorsed fully by the medical community.  
19 Harnessing a potentially effective placebo response to enhance methadone treatment of OUD is  
20 responsive to this NIH call, with the additional boon of very low financial burden and risk to  
21 patients. If our RCT outcome is successful, it would represent an important first step towards a  
22 safe, inexpensive and quick-to-launch adjunct to methadone that could feasibly change front-line  
23 addiction medicine treatment of OUD.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 BMJ Open  
2 Protocol Submission

3 **REFERENCES**

4  
5  
6 1 Gomes T, Tadrous M, Mamdani MM, et al. The Burden of Opioid-Related Mortality in the  
7 United States. *JAMA Network Open* 2018;1(2):e180217.

8  
9 doi:10.1001/jamanetworkopen.2018.0217

10  
11  
12 2 U.S. Department of Health and Human Services (HHS). Office of the Surgeon General, Facing  
13 Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health.

14  
15 Washington, DC: *HHS* 2016.

16  
17  
18 3 Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies—tackling the opioid-  
19 overdose epidemic. *N Engl J Med* 2014;370:2063–66.

20  
21  
22 4 Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid  
23 replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009;3:CD002209.

24  
25  
26 5 Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and  
27 future directions. *Harv Rev Psychiatry* 2015;23(2):63-75.

28  
29  
30 6 Maremmani I, Pacini M, Lubrano S, et al. When “enough” is still not “enough”: Effectiveness  
31 of high-dose methadone in the treatment of heroin addiction. *Heroin Add & Rel Clin Probl*  
32 2003;5:17–32

33  
34  
35 7 Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual  
36 opioid-dependent patients. *PLoS Med* 2006;3(3):e80.

37  
38  
39 8 Strain EC, Stitzer ML, Liebson IA, et al. Methadone dose and treatment outcome. *Drug and*  
40 *Alcohol Dependence* 1993;33:105-17.

41  
42  
43 9 Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of  
44 higher-dose methadone. *J Psychoactive Drugs* 1999;31(2):95-102.

## BMJ Open

## Protocol Submission

10 Adams RG, Capel WC, Bloom WA, et al. Heroin addicts on methadone replacement: a study of dropouts. *Int J Addict* 1971;6(2):269-77.

11 Martin JA, Campbell A, Killip T, et al. QT Interval Screening in Methadone Maintenance Treatment: Report of a SAMHSA Expert Panel. *J Addict Dis* 2011;30(4):283-306.

12 Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. *J Pain* 2014;15(4):321-37.

13 Weimer MB, Chou R. Research gaps on methadone harms and comparative harms: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence Clinical Practice Guideline. *J Pain* 2014;15(4):366-76.

14 Milby JB, Gurwitch RH, Wiebe DJ, et al. Prevalence and diagnostic reliability of methadone maintenance detoxification fear. *Am J Psychiatry* 1986;143(6):739-43.

15 Eklund C, Hiltunen AJ, Melin L, et al. Abstinence fear in methadone maintenance withdrawal: a possible obstacle for getting off methadone. *Subst Use Misuse* 1997;32(6):779-92.

16 Colloca, L. The Placebo Effect in Pain Therapies. *Annu Rev Pharmacol Toxicol* 2019;59:191-211.

17 Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. *N Engl J Med* 2015;373(1):8-9.

18 Colloca L, Flaten MA, Meissner K. (Eds.). *Placebo and pain: from bench to bedside*. Academic Press 2013.

19 Colloca L, Klinger R, Flor H, et al. Placebo analgesia: psychological and neurobiological mechanisms. *Pain* 2013;154(4):511-4.

## BMJ Open

## Protocol Submission

20 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. *J*

*Neurosci* 1999;19(1):484-94.

21 Benedetti F, Pollo A, Lopiano L, et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. *J Neurosci* 2003;23(10):4315-23.

22 Benedetti F, Lanotte M, Lopiano L, et al. When words are painful: unraveling the mechanisms of the nocebo effect. *Neuroscience* 2007;147(2):260-71.

23 Benedetti F. Placebo and Endogenous mechanisms of analgesia. *Handb Exp Pharmacol* 2007;177:393-413.

24 Colloca L, Enck P, DeGrazia D. Relieving pain using dose-extending placebos: a scoping review. *Pain* 2016;157(8):1590-98.

25 Ader R, Mercurio MG, Walton J, et al. Conditioned pharmacotherapeutic effects: a preliminary study. *Psychosom Med* 2010;72(2):192-97.

26 Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. *Child Care Health Dev* 2008;34(1):104-10.

27 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? *J Dev Behav Pediatr* 2010;31(5):369-75.

28 Perlis M, Grandner M, Zee J, et al. Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study. *Sleep Med* 2015;16(9):1160-68.

29 Kirchhof J, Petrakova L, Brinkhoff A, et al. Learned immunosuppressive placebo responses in renal transplant patients. *Proc Natl Acad Sci U S A* 2018;115(16):4223-27.

1 BMJ Open

2 Protocol Submission

3 30 Kaptchuk TJ. Open-label placebo: Reflections on a research agenda. *Perspect Biol Med*  
4 2018; 20:311-34.

5  
6  
7  
8 31 Kaptchuk TJ, Miller FG. Open-label placebo: Can honestly prescribed placebos evoke  
9 meaningful therapeutic benefits? *BMJ* 2018; 363:k3889.

10  
11  
12 32 Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized  
13 controlled trial in irritable bowel syndrome. *PLoS One* 2010;5(12):e15591.

14  
15  
16  
17 33 Carvalho C, Caetano JM, Cunha L, et al. Open-label placebo treatment in chronic low back  
18 pain: a randomized controlled trial. *Pain* 2016;157(12):2766-2772.

19  
20  
21  
22 34 Kam-Hansen S, Jakubowski M, Kelley JM, et al. Altered placebo and drug labeling changes  
23 the outcome of episodic migraine attacks. *Sci Transl Med* 2014;6(218):218ra5.

24  
25  
26  
27 35 Schaefer M, Harke R, Denke C. Open-Label Placebos Improve Symptoms in Allergic  
28 Rhinitis: A Randomized Controlled Trial. *Psychother Psychosom* 2016;85(6):373-374.

29  
30  
31 36 Hoenemeyer TW, Kaptchuk TJ, Mehta TS, et al. Open-Label Placebo Treatment for Cancer-  
32 Related Fatigue: A Randomized-Controlled Clinical Trial. *Sci Rep* 2018;8(1):2784.

33  
34  
35  
36 37 Ongaro G, Kaptchuk TJ. Symptom perception, placebo effects and the Bayesian brain. *Pain*  
37 2018 (in press).

38  
39  
40  
41 38 Belcher AM, Ferré S, Martinez PE, et al. Role of placebo effects in pain and neuropsychiatric  
42 disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2018;87(Pt B):298-306.

43  
44  
45  
46 39 Juliano LM, Brandon TH. Effects of nicotine dose, instructional set, and outcome  
47 expectancies on the subjective effects of smoking in the presence of a stressor. *J Abnorm*  
48 *Psychol* 2002;111(1):88-97.

49  
50  
51  
52 40 Kelemen WL, Kaighobadi F. Expectancy and pharmacology influence the subjective effects  
53 of nicotine in a balanced-placebo design. *Exp Clin Psychopharmacol* 2007;15(1):93-101.

## BMJ Open

## Protocol Submission

41 Rohsenow DJ, Marlatt GA. The balanced placebo design: Methodological considerations. *Addict Behav* 1981;6(2):107-22.

42 Hull JG, Bond CF. Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. *Psychol Bull* 1986;99(3):347-60.

43 Metrik J, Rohsenow DJ, Monti PM, et al. Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. *Exp Clin Psychopharmacol* 2009;17(4):217-25.

44 Marlatt GA, Demming B, Reid JB. Loss of control drinking in alcoholics: an experimental analogue. *J Abnorm Psychol* 1973;81(3):233-41.

45 Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. *J Neurosci* 2003;23(36):11461-68.

46 Skarin K, Sulzer J. Placebo attribution in methadone patients. *Int J Addict* 1978;13(7):1049-59.

47 Colagiuri B, Schenk LA, Kessler MD, et al. The placebo effect: From concepts to genes. *Neuroscience* 2015;307:171-90.

48 Kaptchuk TJ, Miller FG. Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits? *BMJ* 2018;363:k3889.

49 CBS New York. "Seen at 11: Prescription Placebo." Online video clip. *YouTube* 6 Aug 2018. <https://www.youtube.com/watch?v=Jp14Lhl0T9w>

50 Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31(2):73-86.

51 Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. *Am J Drug Alcohol Abuse* 1987;13(3):293-308.

52 MacKillop J, Lisman SA. Effects of a context shift and multiple context extinction on reactivity to alcohol cues. *Exper Clin Psychopharm* 2008;16(4):322-31.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

53 Jobes ML, Aharonovich E, Epstein DH, et al. Effects of preroactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: A randomized study. *J Addict Med* 2015;9(6):491-98.

54 Longwell B, Kestler RJ, Cox TJ. Side effects in methadone patients: a survey of self-reported complaints. *Int J Addict* 1979;14(4):485-94.

55 Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum* 1996;39(6):681-5.

56 Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. *J Exper Psych Gen* 1999;28:78-87.

57 Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. *J Clin Psych* 1995;51:768-74.

58 Carver CS, White TL. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS Scales. *J Pers Soc Psych* 1994;67(2):319-33.

59 Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: Development and validation. *Psychol Assess* 1995;7:524-32.

60 Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. *Psychiatry Res* 1989;28(2):193-213.

61 Krebs EE, Lorenz KA, Blair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 2009;24:733-8.

62 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81.

## BMJ Open

## Protocol Submission

63 Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD. *J Psychoactive Drugs* 2018;50(2):167-76.

64 Collins AB, Bluthenthal RN, Boyd J, et al. Harnessing the language of overdose prevention to advance evidence-based responses to the opioid crisis. *Int J Drug Policy* 2018;55:77-9.

For peer review only

1 BMJ Open  
2 Protocol Submission

3 **Acknowledgments:** Authors would like to acknowledge the following individuals for their  
4 contributions to study implementation: Riti Kotamarti and Olivia Pettingill (assistance with study  
5 conduct); Ray Velencia (patient recruitment assistance); Denisha Pendleton (coordination of  
6 nurses' study roles); and the entire nursing and counseling staff of the University of Maryland  
7 Methadone Treatment Program. We would also like to acknowledge the contributions made by  
8 staff at the Center for Substance Abuse Research (CESAR), University of Maryland for the  
9 following contributions to the study: Jonathan Lewis and Julie Factor (assistance with instrument  
10 development, database development, data analysis); Lynn Wagner and Theresa Hippolyte in the  
11 Division of Forensic Toxicology at the Armed Forces Medical Examiner System (urinalyses).  
12 We used the SPIRIT checklist when writing our report.  
13  
14  
15  
16  
17  
18  
19  
20

21 **Author Statement:** AMB and TOC conduct the study. AMB, TOC, ADG, EWe, DHE, ZK,  
22 CJW, EWi, TJK and LC participated in the original design of the study protocol. SWH is  
23 responsible for placebo pill manufacture. DHE was responsible for the statistical design of the  
24 study. MW, ASB, EM, EWi, EMW and KRH helped to design or choose the study instruments,  
25 develop the database, and will conduct data analysis for the study. AMB wrote the first draft of  
26 the manuscript and all authors contributed revisions and approved the final manuscript.  
27  
28  
29  
30  
31  
32

33 **Funding:** This work was supported by the Foundation for the Science of the Therapeutic  
34 Experience (AMB), funds from the University of Maryland MPowering the State Opioid Use  
35 Disorders Initiative (AMB, EWi, LC), and the Intramural Research Program of the National  
36 Institute on Drug Abuse of the National Institutes of Health (DHE). These funding sources had  
37 no role in the design of this study and will not have any role during its execution, analyses,  
38 interpretation of the data, or decision to submit results.  
39  
40  
41  
42  
43

44 **Competing interests:** None declared.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open  
Protocol Submission

Table 1.

			Phase 1 (Weeks 1 and 2)		Phase 2 (Weeks 3+)		
			Meeting (and Day Number)				
Activity/ Instrument	CRF (Y/N)	Approx. Time to Complete	1	2	3	4	5
			Day 0	Day 14	Day 28	Day 56	Day 84
Verbal assessment of participant interest (intake coordinator)	N	1 minute	X				
Informed Consent Form	Y	5 minutes	X				
Evaluation to Sign Consent	Y	3 minutes	X				
HIPAA Authorization	Y	2 minutes	X				
Inclusion/Exclusion	Y	1 minute	X				
Study Script	Y	3 minutes	X				
Placebo Effect Video	Y	2 minutes	X				
Pill Information Sheet	Y	1 minute	X	X*	X*	X*	
Day 0 Expectancy Assessment	Y	<1 minute	X				
Past 2-Week Drug Use Assessment	Y	2-3 minutes	X	X	X	X	X
BIS/BAS	Y	8 minutes	X		X		X
Pain Catastrophizing Scale	Y	5 minutes	X		X		X

BMJ Open  
Protocol Submission

Pittsburgh Sleep Quality Index	Y	6 minutes	X		X		X
Cleveland Clinic Constipation Scoring	Y	5 minutes	X	X	X	X	X
WHO Quality of Life Assessment	Y	10 minutes	X	X	X	X	X
Craving Assessment	Y	<1 minute	X	X	X	X	X
SOWS	Y	5 minutes	X	X	X	X	X
OOWS	Y	5 minutes	X	X	X	X	X
Baseline Drug Use History	Y	10 minutes	X				
Randomization	Y	1 minute	X				
Order Form*	Y	1 minutes	X	X	X		
Urine Sample	Y	3 minutes	X	X	X	X	X
Payment Logs	Y	3 minutes	X	X	X	X	X
Phase I Compliance*	Y	<1 minute		X			
Methadone Side Effects Checklist	Y	5-7 minutes		X	X	X	X
MCQ	Y	4 minutes		X		X	X
BIS-11	Y	8 minutes		X			
Post-Baseline Drug Use History	Y	5 minutes		X	X	X	X
Phase II Compliance*	Y	<1 minute			X	X	X
Day 28 Expectancy Outcomes (group dependent)	Y	<1 minute				X	X
PEG Pain Scale	Y	2 minutes			X		
Exit Interview	Y	4 minutes					

1 BMJ Open  
2 Protocol Submission

3 Table 1. Assessment time line. \* Indicates assessments that were administered only to  
4 participants in Placebo Dose-Extension Group (PDE); CRF= case report form  
5  
6

7  
8 Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment  
9 As Usual group; PDE = Placebo Dose Extension group  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Hypothetical Methadone Treatment Course and Expected Outcome




Figure 1. Hypothetical Methadone Treatment Course and Expected Outcome. TAU = Treatment As Usual group; PDE = Placebo Dose Extension group

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	26
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 26
Roles and responsibilities:	#5b	Name and contact information for the trial sponsor	1



1	sponsor contact			
2	information			
3				
4	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	26
5	responsibilities:		collection, management, analysis, and interpretation of	
6	sponsor and funder		data; writing of the report; and the decision to submit the	
7			report for publication, including whether they will have	
8			ultimate authority over any of these activities	
9				
10				
11				
12	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	26
13	responsibilities:		centre, steering committee, endpoint adjudication	
14	committees		committee, data management team, and other individuals or	
15			groups overseeing the trial, if applicable (see Item 21a for	
16			data monitoring committee)	
17				
18				
19				
20	Background and	#6a	Description of research question and justification for	6
21	rationale		undertaking the trial, including summary of relevant studies	
22			(published and unpublished) examining benefits and harms	
23			for each intervention	
24				
25				
26				
27	Background and	#6b	Explanation for choice of comparators	8
28	rationale: choice of			
29	comparators			
30				
31				
32	Objectives	#7	Specific objectives or hypotheses	8
33				
34				
35	Trial design	#8	Description of trial design including type of trial (eg, parallel	8-9
36			group, crossover, factorial, single group), allocation ratio,	
37			and framework (eg, superiority, equivalence, non-inferiority,	
38			exploratory)	
39				
40				
41				
42	Study setting	#9	Description of study settings (eg, community clinic,	9
43			academic hospital) and list of countries where data will be	
44			collected. Reference to where list of study sites can be	
45			obtained	
46				
47				
48	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	10
49			eligibility criteria for study centres and individuals who will	
50			perform the interventions (eg, surgeons, psychotherapists)	
51				
52				
53				
54	Interventions:	#11a	Interventions for each group with sufficient detail to allow	11-12
55	description		replication, including how and when they will be	
56			administered	
57				
58				
59				
60				

1	Interventions:	#11b	Criteria for discontinuing or modifying allocated	12
2	modifications		interventions for a given trial participant (eg, drug dose	
3			change in response to harms, participant request, or	
4			improving / worsening disease)	
5				
6				
7				
8	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	12
9	adherence		and any procedures for monitoring adherence (eg, drug	
10			tablet return; laboratory tests)	
11				
12				
13	Interventions:	#11d	Relevant concomitant care and interventions that are	11
14	concomitant care		permitted or prohibited during the trial	
15				
16				
17	Outcomes	#12	Primary, secondary, and other outcomes, including the	12-15
18			specific measurement variable (eg, systolic blood pressure),	
19			analysis metric (eg, change from baseline, final value, time	
20			to event), method of aggregation (eg, median, proportion),	
21			and time point for each outcome. Explanation of the clinical	
22			relevance of chosen efficacy and harm outcomes is strongly	
23			recommended	
24				
25				
26				
27				
28	Participant timeline	#13	Time schedule of enrolment, interventions (including any	27
29			run-ins and washouts), assessments, and visits for	
30			participants. A schematic diagram is highly recommended	
31			(see Figure)	
32				
33				
34				
35	Sample size	#14	Estimated number of participants needed to achieve study	15
36			objectives and how it was determined, including clinical and	
37			statistical assumptions supporting any sample size	
38			calculations	
39				
40				
41				
42	Recruitment	#15	Strategies for achieving adequate participant enrolment to	15
43			reach target sample size	
44				
45				
46	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	10
47	generation		computer-generated random numbers), and list of any	
48			factors for stratification. To reduce predictability of a random	
49			sequence, details of any planned restriction (eg, blocking)	
50			should be provided in a separate document that is	
51			unavailable to those who enrol participants or assign	
52			interventions	
53				
54				
55				
56				
57	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	10-11
58	concealment		central telephone; sequentially numbered, opaque, sealed	
59				
60				

1	mechanism		envelopes), describing any steps to conceal the sequence	
2			until interventions are assigned	
3				
4	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	10-11
5	implementation		participants, and who will assign participants to	
6			interventions	
7				
8				
9	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	11
10			trial participants, care providers, outcome assessors, data	
11			analysts), and how	
12				
13				
14	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	n/a
15	emergency		permissible, and procedure for revealing a participant's	
16	unblinding		allocated intervention during the trial	
17				
18				
19				
20	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	13-15,
21			and other trial data, including any related processes to	27
22			promote data quality (eg, duplicate measurements, training	
23			of assessors) and a description of study instruments (eg,	
24			questionnaires, laboratory tests) along with their reliability	
25			and validity, if known. Reference to where data collection	
26			forms can be found, if not in the protocol	
27				
28				
29				
30				
31	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	16
32	retention		up, including list of any outcome data to be collected for	
33			participants who discontinue or deviate from intervention	
34			protocols	
35				
36				
37				
38	Data management	#19	Plans for data entry, coding, security, and storage, including	16
39			any related processes to promote data quality (eg, double	
40			data entry; range checks for data values). Reference to	
41			where details of data management procedures can be	
42			found, if not in the protocol	
43				
44				
45				
46	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	16
47			outcomes. Reference to where other details of the statistical	
48			analysis plan can be found, if not in the protocol	
49				
50				
51	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	16
52	analyses		adjusted analyses)	
53				
54				
55	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	16
56	population and		adherence (eg, as randomised analysis), and any statistical	
57	missing data		methods to handle missing data (eg, multiple imputation)	
58				
59				
60				

1	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary	17
2	formal committee		of its role and reporting structure; statement of whether it is	
3			independent from the sponsor and competing interests; and	
4			reference to where further details about its charter can be	
5			found, if not in the protocol. Alternatively, an explanation of	
6			why a DMC is not needed	
7				
8				
9				
10				
11	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	n/a
12	interim analysis		including who will have access to these interim results and	
13			make the final decision to terminate the trial	
14				
15				
16	Harms	#22	Plans for collecting, assessing, reporting, and managing	17
17			solicited and spontaneously reported adverse events and	
18			other unintended effects of trial interventions or trial conduct	
19				
20				
21	Auditing	#23	Frequency and procedures for auditing trial conduct, if any,	n/a
22			and whether the process will be independent from	
23			investigators and the sponsor	
24				
25				
26				
27	Research ethics	#24	Plans for seeking research ethics committee / institutional	17
28	approval		review board (REC / IRB) approval	
29				
30				
31	Protocol	#25	Plans for communicating important protocol modifications	17
32	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
33			relevant parties (eg, investigators, REC / IRBs, trial	
34			participants, trial registries, journals, regulators)	
35				
36				
37	Consent or assent	#26a	Who will obtain informed consent or assent from potential	9-10
38			trial participants or authorised surrogates, and how (see	
39			Item 32)	
40				
41				
42				
43	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
44	ancillary studies		participant data and biological specimens in ancillary	
45			studies, if applicable	
46				
47				
48	Confidentiality	#27	How personal information about potential and enrolled	16-17
49			participants will be collected, shared, and maintained in	
50			order to protect confidentiality before, during, and after the	
51			trial	
52				
53				
54				
55	Declaration of	#28	Financial and other competing interests for principal	27
56	interests		investigators for the overall trial and each study site	
57				
58				
59	Data access	#29	Statement of who will have access to the final trial dataset,	17
60				

		and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	17-18
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 10. September 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)